Original Article
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
N Engl J Med 2005; 352:2589-2597June 23, 2005
- Abstract
Background
We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non–small-cell lung cancer.
Methods
We randomly assigned patients with completely resected stage IB or stage II non–small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen.
Results
A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03).
Conclusions
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non–small-cell lung cancer.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Survival among Patients Who Received Adjuvant Vinorelbine plus Cisplatin and Those Who Underwent Observation Alone.Table 1
Baseline Characteristics of the Randomized Patients.Article Activity
- Article
Lung cancer is the leading cause of death from cancer in North America.1 For early-stage non–small-cell lung cancer, surgical resection is the treatment of choice, yet five-year survival ranges from only 30 percent to 60 percent.2 Recurrences leading to death occur mainly in extrathoracic sites after complete resection. Therefore, there is a need for effective systemic therapy to reduce the risk of recurrence and improve survival.2,3
A British Medical Research Council meta-analysis of cisplatin-based chemotherapy after surgery for stage I through stage III non–small-cell lung cancer showed a 13 percent reduction in the risk of death and an absolute improvement in survival of 5 percent at five years, but when compared with observation alone after surgery, the difference was statistically insignificant (P=0.08).4 More recently, a large international trial of adjuvant chemotherapy that used cisplatin plus either a vinca alkaloid or etoposide (International Adjuvant Lung Cancer Trial [IALT]) reported similar results, with a 4.1 percent improvement in five-year survival (hazard ratio, 0.86; P<0.03).5 With such small gains in survival, neither physicians nor their patients have been convinced that the toxicity of adjuvant chemotherapy is justified in the treatment of non–small-cell lung cancer. Thus, observation alone has been the standard of care after resection of early-stage non–small-cell lung cancer.
Newer chemotherapeutic agents (vinorelbine, gemcitabine, taxanes, and camptothecins), when coupled with a platinum derivative, have significantly increased response and overall survival rates as compared with previous regimens in advanced non–small-cell lung cancer.6,7 Trials confirming the superior efficacy of vinorelbine in combination with platinum as compared with previous combinations were published in the early 1990s.6,7 Simultaneously, serotonin-receptor antagonists were shown to be effective in reducing the severity of cisplatin-induced emesis.8 Thus, an outpatient regimen of vinorelbine plus cisplatin as adjuvant chemotherapy, administered with antiemetics and supportive care, was considered an excellent choice and led to the initiation of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial in patients with completely resected stage IB or stage II non–small-cell lung cancer.
Methods
Study Design
This study was a North American intergroup, phase 3, randomized trial of adjuvant vinorelbine plus cisplatin after resection of stage IB or stage II non–small-cell lung cancer. It was begun in April 1994 in Canada. The American cooperative groups (Cancer and Leukemia Group B [CALGB], Southwest Oncology Group [SWOG], and Eastern Cooperative Oncology Group [ECOG]) joined in 1998. Within six weeks after surgery, eligible patients were randomly assigned in a 1:1 ratio9 to adjuvant vinorelbine plus cisplatin or observation. Patients were stratified according to nodal status (N0 vs. N1) and the presence or absence of a ras mutation. The primary end point was overall survival. Secondary end points included recurrence-free survival and the safety, toxicity, and quality of life associated with this regimen.
The protocol was approved by the institutional review boards at all the institutions, and all patients provided written informed consent. Funding was provided by the National Cancer Institute of Canada, the National Cancer Institute of the United States, and GlaxoSmithKline. Data were collected, managed, and analyzed by the National Cancer Institute of Canada Clinical Trials Group. GlaxoSmithKline had no part in writing the manuscript but did review an early draft, with no right to change the text or its conclusions. There was no contractual obligation with GlaxoSmithKline with respect to the decision to submit the manuscript for publication, and the company had no influence on the content or preparation of this article. Dr. Winton, the study chair, vouches for the accuracy and completeness of the data.
Eligibility Criteria
Patients 18 years of age or older with completely resected T2N0, T1N1, or T2N1 non–small-cell lung cancer with acceptable baseline characteristics and an ECOG performance status of 0 or 1 were eligible. All patients had a preoperative computed tomographic scan, and intraoperative mediastinal lymph-node resection or biopsy of nodes that were 1.5 cm or larger was mandatory. Patients with incomplete preoperative or intraoperative staging, incomplete resection, wedge or segmental resection, involvement of tracheobronchial angle nodes (station 10) or more central mediastinal nodes, mixed histologic features, a T3 tumor, or diffuse lobar or multifocal bronchioalveolar carcinoma and patients who had had breast cancer, renal-cell carcinoma, melanoma, or other cancers treated within the previous five years were ineligible. Patients with clinically significant cardiac dysfunction, active infection, or neurologic or psychiatric disorders were also ineligible.
Randomization and Treatment Regimen
Treatment started within two days after randomization. A regimen of 50 mg of cisplatin per square meter of body-surface area on days 1 and 8 every 4 weeks for four cycles and 25 mg of vinorelbine per square meter weekly for 16 weeks was prescribed. The protocol originally called for 30 mg of vinorelbine per square meter, but the dose was amended in August 1995 because of hematologic toxicity (only 18 patients received 30 mg of vinorelbine per square meter). All patients received ondansetron, commonly with a corticosteroid, and chemotherapy was adjusted for toxicity according to protocol guidelines.
Follow-up
Follow-up clinical examinations and chest radiography were performed every three months for three years and every six months thereafter. Data assessing quality of life were collected prospectively in both groups, but the details of the findings and data analysis are beyond the scope of this article.
ras Evaluation
Participating centers submitted fresh-frozen primary tumor or paraffin-embedded blocks of tissue specimens to a central laboratory for ras mutation analysis of codons 12, 13, and 61 of the H-ras, K-ras, and N-ras genes by allele-specific oligonucleotide hybridization. The results were confirmed by sequencing.10
Statistical Analysis
A sample size of 450 patients recruited over a period of 6.75 years, with less than 1 year of follow-up, and 198 events (deaths) were required to provide the study with 80 percent power to detect a 10 percent improvement in survival (from an estimated 3-year survival rate of 60 percent) with a one-sided 5 percent significance level. Two planned interim analyses were conducted in March 2000 and March 2002, after 64 and 122 deaths, respectively. The database was locked in April 2004, and all randomized patients were included in the final analysis, which was based on the intention-to-treat method. Patients who received any protocol treatment were included in toxicity analyses.
Median survival, 95 percent confidence intervals, and Kaplan–Meier estimates of recurrence-free survival and overall survival were calculated according to standard methods.11-13 The Cox regression model, stratified according to nodal status — including the status of ras mutations (unknown vs. mutation vs. wild type) as a covariate — was used to test the difference in overall and recurrence-free survival between the study groups.13 For the primary analysis of overall survival, the stagewise ordering method was used to obtain the P value adjusted for the two planned interim analyses.14 An unadjusted log-rank test and an exploratory, stratified Cox regression model analysis, adjusted for ras status, age, sex, performance status (ECOG 0 or 1), extent of resection, and histologic features, were performed. To test whether treatment effects were homogeneous across the stratification factors, subgroup analyses of overall and recurrence-free survival with the use of proportional-hazards models with interaction terms were included.13 All P values reported are the result of two-sided tests.
Results
Characteristics of the Patients
Between July 1994 and April 2001, 532 patients were registered, and 482 were randomly assigned to observation (240 patients) or chemotherapy (242). Fifty registered patients (9.4 percent) never underwent randomization, owing to patient refusal (36 patients), postoperative death (2), intercurrent illness (4), decreased performance status (2), metastases (2), and ineligibility (4). Forty-one patients (8.5 percent) — 22 in the observation group and 19 in the chemotherapy group — who underwent randomization did not fully meet eligibility criteria: 7 had incomplete staging or screening data, 15 had tumors that were more advanced than stage II, 18 had abnormal laboratory results, and 1 had incomplete resection.
Follow-up ranged from 1.5 to 9.3 years (median, 5.1 years) in the chemotherapy group and 0.4 to 9.0 years (median, 5.3 years) in the observation group. Three patients (0.6 percent) were lost to follow-up, two in the treatment group at 6.3 and 7.0 years after randomization and one in the observation group at 4.1 years after randomization.
The baseline characteristics of the patients are shown in Table 1Table 1
Baseline Characteristics of the Randomized Patients.. The two groups were evenly distributed with respect to important prognostic variables, including age, sex, ECOG performance status, and histologic features.Delivery and Toxicity of Chemotherapy
Data concerning drug delivery, treatment compliance, and quality of life were reported previously.15,16 At least one dose of medication was received by 231 patients (95.5 percent); 11 of the patients randomly assigned to vinorelbine plus cisplatin (4.5 percent) did not receive chemotherapy (9 patients refused treatment, 1 was ineligible, and 1 was randomly assigned to observation erroneously) (Table 2Table 2
Delivery of Chemotherapy for Patients Randomly Assigned to Vinorelbine plus Cisplatin.). The median number of cycles delivered was three. Fifty-eight percent of the patients received three or more cycles of cisplatin, 77 percent had at least one dose reduction or omission, and 55 percent required one dose delay or more, most related to neutropenia at the expected time of vinorelbine administration on day 15 (cycle week 3). Seventy-three of the patients who received at least one dose (32 percent) required hospitalization — 16 (7 percent) for administration of chemotherapy, 14 (6 percent) for reasons unrelated to treatment (with death in 1 patient), and 43 (19 percent) for medical problems related to toxicity (with death in 1 patient).Neutropenia was the most common severe toxic effect of chemotherapy; 73 percent of patients had grade 3 or 4 neutropenia, 7 percent had grade 3 or 4 anemia, and 1 percent had grade 3 thrombocytopenia (Table 3Table 3
Drug-Related Adverse Events among Patients Who Received at Least One Dose of Vinorelbine plus Cisplatin.). Colony-stimulating factors were administered to 15 percent of the patients and febrile neutropenia occurred in 7 percent. Severe nonhematologic toxic effects from chemotherapy were uncommon. Grade 3 or 4 anorexia, nausea, or vomiting was reported by 10 percent, 10 percent, and 7 percent of the patients, respectively. Grade 3 or 4 sensory neurotoxicity, motor neurotoxicity, or hearing loss was observed in 2 percent, 3 percent, and 2 percent, respectively.Two patients (0.8 percent) died because of treatment-related toxicity — one during chemotherapy from sepsis secondary to febrile neutropenia, and one six months after chemotherapy from interstitial lung disease, first documented during treatment.
Relapse-Free and Overall Survival
Recurrence was documented in 206 patients (42.7 percent) — 87 in the group assigned to vinorelbine and cisplatin (36.0 percent) and 119 in the observation group (49.6 percent) (P=0.003). The Kaplan–Meier estimates of recurrence-free survival are shown in Figure 1AFigure 1
Kaplan–Meier Estimates of Survival among Patients Who Received Adjuvant Vinorelbine plus Cisplatin and Those Who Underwent Observation Alone.. Chemotherapy significantly prolonged recurrence-free survival as compared with observation (hazard ratio for recurrence, 0.60; 95 percent confidence interval, 0.45 to 0.79; P<0.001). The median recurrence-free survival was 46.7 months in the observation group and had not been reached in the chemotherapy group at the time the database was locked. The five-year recurrence-free survival rates were 61 percent (95 percent confidence interval, 54 to 68 percent) in the vinorelbine–cisplatin group and 49 percent (95 percent confidence interval, 42 to 55 percent) in the observation group (P=0.08). Use of the stratified Cox regression model showed that only chemotherapy (P<0.001) and squamous histologic features (P=0.002) were associated with significantly prolonged recurrence-free survival.A total of 197 patients (111 in the observation group and 86 in the chemotherapy group) had died when the database was locked. Eighty-two percent of them died from recurrent lung cancer (92 in the observation group and 70 in the chemotherapy group), 5 percent from second malignant conditions (5 and 4, respectively), and 12 percent from other causes (11 and 13, respectively). Of the 11 patients in the observation group who died from other causes, 6 died from myocardial infarction, 2 from pulmonary emboli, 2 from an exacerbation of chronic obstructive pulmonary disease, and 1 from a ruptured aortic aneurysm. Of the 13 patients in the vinorelbine–cisplatin group who died from other causes, 6 died from myocardial infarction, 2 from pulmonary emboli, 1 from chronic obstructive pulmonary disease, 1 from gastrointestinal bleeding, 1 from stroke, and 2 from alcohol toxicity.
Figure 1B shows Kaplan–Meier estimates of overall survival. The median survival after chemotherapy was significantly prolonged, at 94 months (95 percent confidence interval, 73 to not reached), as compared with 73 months (95 percent confidence interval, 48 to not reached) in the observation group (hazard ratio, 0.69; 95 percent confidence interval, 0.52 to 0.91; P=0.009; P=0.04 after adjustment for interim analyses). There was an absolute survival advantage of 15 percentage points at five years — 69 percent (95 percent confidence interval, 62 to 75 percent) in the vinorelbine–cisplatin group and 54 percent (95 percent confidence interval, 48 to 61 percent) with observation alone (P=0.03).
Subgroup analyses according to stratification factors did not show a statistically significant improvement in overall survival among patients with stage IB non–small-cell lung cancer in the chemotherapy group as compared with the observation group (P=0.79) (Figure 1C). The median survival among patients with stage II non–small-cell lung cancer was 41 months in the observation group and 80 months in the chemotherapy group (hazard ratio, 0.59; 95 percent confidence interval, 0.42 to 0.85; P=0.004) (Figure 1D). These findings must be considered with caution, given that no statistically significant effect of treatment according to disease stage was detected (P=0.13).
The status of ras mutations in the tumors is known in 450 patients (93 percent). The median survival among patients with wild-type ras in the observation group was 74 months and had not been reached in the group that received chemotherapy (hazard ratio, 0.69; 95 percent confidence interval, 0.49 to 0.98; P=0.03). In contrast, adjuvant chemotherapy did not seem to confer a survival advantage in patients whose tumors had ras mutations (hazard ratio, 0.95; 95 percent confidence interval, 0.53 to 1.71; P=0.87). However, in the interaction analysis, the effect of the status of ras mutations on the outcome of treatment was not statistically significant (P=0.29).
In the planned stratified Cox regression analysis, significant factors that were associated with improved survival included chemotherapy as compared with observation (hazard ratio for the difference in survival, 0.67; 95 percent confidence interval, 0.51 to 0.89; P=0.006) and squamous histologic features as compared with adenocarcinomas (P=0.005). In contrast, older age (P=0.001), male sex (P=0.03), and pneumonectomy as compared with lesser resection (P=0.02) were associated with shorter survival; ras mutation was not a predictor of survival.
Discussion
This prospective, randomized trial documents the benefit of adjuvant vinorelbine plus cisplatin in completely resected, early-stage non–small-cell lung cancer. The overall survival advantage at five years was 15 percentage points (P=0.03), exceeding the marginal benefit (5 percentage points) observed in the British Medical Research Council meta-analysis4 and the large IALT trial, which reported a survival advantage of 4.1 percentage points at five years (P<0.03).5
Three other trials of adjuvant chemotherapy for non–small-cell lung cancer undertaken during the past decade have been reported. Keller et al.17 reported the results of the ECOG trial of adjuvant etoposide plus cisplatin and radiotherapy as compared with radiotherapy alone after resection of stage II or IIIA non–small-cell lung cancer. There was no difference between the groups in the recurrence rate or in survival, and greater toxicity was observed in the chemoradiotherapy group in this trial. Similarly, the Adjuvant Lung Project Italy (ALPI)18 found no benefit from three cycles of mitomycin C, vindesine, and cisplatin in 1209 patients with stage I to IIIA non–small-cell lung cancer. Finally, Waller et al.19 (of the Big Lung Trial) reported that 381 patients with non–small-cell lung cancer who were randomly assigned to various platinum-based regimens in a neoadjuvant or adjuvant setting had no benefit from treatment.
What accounts for the results of the current trial? Several important factors should be considered. The superiority of the vinorelbine–cisplatin combination has been well established in patients with advanced non–small-cell lung cancer, in whom it has been shown to provide significantly better response rates and overall survival than other regimens.7,20-26 With the exception of IALT5 and the Big Lung Trial,19 in which only 27 percent and 22 percent of patients, respectively, received vinorelbine plus cisplatin, all the negative trials used older chemotherapeutic combinations with comparatively less efficacy in advanced non–small-cell lung cancer.
The CALGB protocol 9633 trial, in which another current adjuvant regimen (paclitaxel plus carboplatin) was compared with observation alone after complete resection of stage IB non–small-cell lung cancer, found a similar improvement in survival rates (an improvement of 12 percentage points at four years, vs. 15 percentage points at five years in the current trial) and a similar, significant reduction in the risk of death from recurrent lung cancer.27 Vinorelbine plus cisplatin and paclitaxel plus carboplatin have similar efficacy in advanced non–small-cell lung cancer22; hence, it is not surprising that they have been found to confer similar survival benefits in the adjuvant setting.
All patients in the ECOG trial of adjuvant therapy,17 and 31 percent and 43 percent of patients in IALT5 and the ALPI trial,18 respectively, received radiotherapy in addition to chemotherapy, with variable delivery of the dosage of radiotherapy between the treatment and observation groups. Radiotherapy may have had a deleterious effect on outcomes, since a meta-analysis of postoperative radiotherapy (known as PORT) showed that the risk of death increased by 21 percent with a 7 percent reduction in two-year survival with postoperative radiation.28 Furthermore, the Medical Research Council meta-analysis of adjuvant radiotherapy with or without chemotherapy showed no benefit from chemoradiotherapy and no survival benefit from radiotherapy alone.4 Finally, the cumulative toxic effects of chemoradiotherapy may limit the delivery of cytotoxic systemic chemotherapy and hence reduce efficacy.
Only patients with early-stage (stage IB or stage II) non–small-cell lung cancer were included in CALGB protocol 963327 and this trial. Previous trials included significant numbers of patients with resected stage IIIA non–small-cell lung cancer. Patients with stage IIIA disease have a high likelihood of harboring occult extrathoracic disease, are heterogeneous in terms of the extent (burden or bulk) of disease and number of nodal stations involved, frequently have a poor performance status, often require pneumonectomy, and do not tolerate chemotherapy well.2,3,15 These factors may have contributed to the inability of these earlier trials to show a survival benefit from chemotherapy.
Subgroup analyses indicate that the survival advantage in our trial was most prominent in patients with stage II disease. We cannot explain why the benefit in patients with stage IB disease was less and did not reach statistical significance (7 percent benefit at five years, vs. 20 percent among those with stage II disease). The number of patients with stage IB disease was small, the number of events was smaller than had been anticipated when the subgroup analysis was planned, and the statistical test for stage-by-treatment interaction was not significant (P=0.13). Therefore, it is important not to place too much emphasis on this subgroup analysis.
Patients with tumors containing ras gene mutations have poorer survival after surgery than those without ras mutations, but to our knowledge, previous studies have not prospectively examined the status of ras genes in relation to survival or the response to adjuvant chemotherapy.29-31 The observation that patients with ras mutations did not benefit from adjuvant chemotherapy, whereas those with wild-type ras did, requires further analysis and validation, especially because the secondary analysis for interaction terms failed to show statistically significant differences between the groups (P=0.29).
The vinorelbine–cisplatin regimen was associated with acceptable adverse event rates after reduction of the vinorelbine dose from 30 to 25 mg per square meter weekly. The rates of febrile neutropenia (7 percent) and of treatment-related death (0.8 percent) are similar to the rates of these events in other reports. Cisplatin-based regimens are associated with enhanced efficacy and toxicity as compared with carboplatin-based therapy32,33; yet in CALGB protocol 9633,27 33 percent of patients required dose reductions, and not all completed a full course of therapy. Our quality-of-life analyses showed that, despite toxicity, the decline in function- and symptom-related domains during chemotherapy in the current trial was limited and resolved rapidly (within three months after completion of therapy).16
This study indicates that adjuvant treatment with vinorelbine plus cisplatin can be safely administered in the outpatient setting with limited toxicity and is beneficial in non–small-cell lung cancer. We believe that a brief course of such chemotherapy should become the standard of care for patients with good performance status after complete resection of stage IB or stage II non–small-cell lung cancer.
Supported by grants (4493 and 12150) from the Canadian Cancer Society and the National Cancer Institute of Canada and by grants (CA04326 and CA31946, to Drs. Rigas and Demmy) from the National Cancer Institute and Cancer and Leukemia Group B.
We are indebted to the patients who participated in this study; to the trial committee; to the investigators, pharmacists, and clinical research associates from the National Cancer Institute of Canada Clinical Trials Group, SWOG, ECOG, and CALGB; to the members of the Canadian Association for Thoracic Surgery who supported this trial from the outset; to the members of the data safety and monitoring committee; and to the central office staff of the National Cancer Institute of Canada Clinical Trials Group who helped conduct this trial.
Source Information
From the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont. (T.W., M.J., C.B., Y.C., G.G., R.I., D.B., J.A., K.D., L.S., B.G., M.-S.T., F.S.); Southwest Oncology Group, San Antonio, Tex. (R.L., E.V., D.G.); Eastern Cooperative Oncology Group, Boston (D.J., W.F., K.K.); and Cancer and Leukemia Group B, Chicago (J.R., T.D.).
Address reprint requests to Dr. Winton at 2D2.09 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th St., Edmonton, AB T6G 2B7, Canada, or at twinton@cha.ab.ca.
- References
References
1
Jemal A ,Tiwari RC ,Murray T , et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
CrossRef | Web of Science | Medline2
Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of nonsmall cell lung cancer. In: Shields TW, Lo Cicero III J, Ponn R, Rusch VW, eds. General thoracic surgery. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:1548-87.
3
Mountain CF . Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717
CrossRef | Web of Science | Medline4
Non-small Cell Lung Cancer Collaborative Group
CrossRef | Web of Science5
The International Adjuvant Lung Cancer Trial Collaborative Group
Full Text | Web of Science | Medline6
Shepherd FA. Chemotherapy for non-small-cell lung cancer. In: Pearson FG, Cooper JD, Deslauriers J, et al., eds. Thoracic surgery. 2nd ed. New York: Churchill Livingstone, 2002:859-74.
7
Le Chevalier T ,Brisgand D ,Douillard JY , et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367
Web of Science | Medline8
Italian Group for Antiemetic Research
CrossRef | Web of Science | Medline9
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline10
Tsao M-S ,Liu N ,Nicklee T ,Shepherd F ,Viallet J . Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 1997;3:1807-1814
Web of Science | Medline11
Brookmeyer R, Crowley JJ. A confidence interval for median survival time. Biometrics 1982;38:29-41.
12
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science13
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22014
Tsiatis AA ,Rosner GL ,Mehta CR . Exact confidence intervals following a group sequential test. Biometrics 1984;40:797-803
CrossRef | Web of Science | Medline15
Alam N ,Shepherd FA ,Winton T , et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 2005;47:385-394
CrossRef | Web of Science | Medline16
Beziak A ,Winton T , Ding K et al. Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10). Lung Cancer 2003;41:Suppl 2:S20-S20 abstract.
CrossRef17
Keller SM ,Adak S ,Wagner H , et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000;343:1217-1222
Full Text | Web of Science | Medline18
Scagliotti GV ,Fossati R ,Torri V , et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461
CrossRef | Web of Science | Medline19
Waller D ,Peake MD ,Stephens RJ , et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182
CrossRef | Web of Science | Medline20
Cullen M . Chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax 2003;58:352-356
CrossRef | Web of Science | Medline21
Socinski MA ,Morris DE ,Masters GA , et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123:Suppl 1:226S-243S
CrossRef | Web of Science | Medline22
Kelly K ,Crowley J ,Bunn PA Jr , et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218
Web of Science | Medline23
Keller SM ,Vangel MG ,Adak S , et al. The influence of gender on survival and tumour recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2002;37:303-309
CrossRef | Web of Science | Medline24
Bonomi P ,Kim K ,Fairclough D , et al. Comparison of survival and quality of life in non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000;18:623-631
Web of Science | Medline25
Giaccone G ,Splinter TA ,Debruyne S , et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998;16:2133-2141
Web of Science | Medline26
Bunn PA Jr ,Kelly K . New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100
Web of Science | Medline27
Strauss GM ,Herndon J ,Maddaus MA , et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22:Suppl 14S:7019-701928
PORT Meta-analysis Trialists Group
CrossRef | Web of Science | Medline29
Mitsudomi T ,Steinberg SM ,Oie HK , et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002
Web of Science | Medline30
Sugio K ,Ishida T ,Yokoyama H ,Inoue T ,Sugimachi K ,Sasazuki T . Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-2906
Web of Science | Medline31
Rosell R ,Li S ,Skacel Z , et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8:2407-2412
Web of Science | Medline32
Zojwalla NJ ,Raftopoulos H ,Gralla RJ . Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. J Clin Oncol 2004;22:Suppl 14S:7068-706833
Soria JC ,Le Chevalier T . Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 2002;13:1515-1517
CrossRef | Web of Science | Medline
- Citing Articles (429)
Citing Articles
1
Sofia R. Gameiro, Jorge A. Caballero, James W. Hodge. (2012) Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing. Cancer Biotherapy & Radiopharmaceuticals120208100150001
CrossRef2
Hai-Long Zhang, Li Ruan, Li-Mou Zheng, David Whyte, Chi-Meng Tzeng, Xi-Wu Zhou. (2012) Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer
CrossRef3
Sonosuke Tanaka, Noboru Hattori, Nobuhisa Ishikawa, Hiroyasu Shoda, Atsushi Takano, Ryohei Nishino, Morihito Okada, Koji Arihiro, Kouki Inai, Hironobu Hamada, Akihito Yokoyama, Nobuoki Kohno. (2012) Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. International Journal of Cancer 130:2, 377-387
CrossRef4
Johannes R Kratz, Jianxing He, Stephen K Van Den Eeden, Zhi-Hua Zhu, Wen Gao, Patrick T Pham, Michael S Mulvihill, Fatemeh Ziaei, Huanrong Zhang, Bo Su, Xiuyi Zhi, Charles P Quesenberry, Laurel A Habel, Qiuhua Deng, Zongfei Wang, Jiangfen Zhou, Huiling Li, Mei-Chun Huang, Che-Chung Yeh, Mark R Segal, M Roshni Ray, Kirk D Jones, Dan J Raz, Zhidong Xu, Thierry M Jahan, David Berryman, Biao He, Michael J Mann, David M Jablons. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. The Lancet
CrossRef5
D.-T. Chen, Y.-L. Hsu, W. J. Fulp, D. Coppola, E. B. Haura, T. J. Yeatman, W. D. Cress. (2011) Prognostic and Predictive Value of a Malignancy-Risk Gene Signature in Early-Stage Non-Small Cell Lung Cancer. JNCI Journal of the National Cancer Institute
CrossRef6
Martin Filipits, Robert Pirker. (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74:3, 355-363
CrossRef7
Anna-Liisa Kautio, Maija Haanpää, Hannu Kautiainen, Eija Kalso, Tiina Saarto. (2011) Burden of chemotherapy-induced neuropathy—a cross-sectional study. Supportive Care in Cancer 19:12, 1991-1996
CrossRef8
Luca Paoletti, Nicholas J. Pastis, Chadrick E. Denlinger, Gerard A. Silvestri. (2011) A Decade of Advances in Treatment of Early-Stage Lung Cancer. Clinics in Chest Medicine 32:4, 827-838
CrossRef9
Yin Tian, Jun Zhang, Shuangshuang Yan, Li Qiu, Zheng Li. (2011) FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer
CrossRef10
Hiroshi Date. (2011) The Impact of Complete Lymph Node Dissection for Lung Cancer on the Postoperative Course. Thoracic Surgery Clinics
CrossRef11
Kristin A. Higgins, Junzo P. Chino, Mark Berry, Neal Ready, Jessamy Boyd, David S. Yoo, Chris R. Kelsey. (2011) Local Failure in Resected N1 Lung Cancer: Implications for Adjuvant Therapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef12
Shamus R. Carr, Matthew J. Schuchert, Arjun Pennathur, David O. Wilson, Jill M. Siegfried, James D. Luketich, Rodney J. Landreneau. (2011) Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system. The Journal of Thoracic and Cardiovascular Surgery
CrossRef13
A.G. Pallis, M. Scarci. (2011) Are we treating enough elderly patients with early stage non-small cell lung cancer?. Lung Cancer 74:2, 149-154
CrossRef14
Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances A Shepherd. (2011) Non-small-cell lung cancer. The Lancet 378:9804, 1727-1740
CrossRef15
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef16
Songshu Meng, Zhizhi Zhou, Fei Chen, Xiangang Kong, Huairan Liu, Ke Jiang, Wenbo Liu, Maozhi Hu, Xiaorong Zhang, Chan Ding, Yantao Wu. (2011) Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Letters
CrossRef17
Lyall A. Gorenstein, Joshua R. Sonett. (2011) The Surgical Management of Stage I and Stage II Lung Cancer. Surgical Oncology Clinics of North America 20:4, 701-720
CrossRef18
Roy H. Decker, Corey J. Langer, Kenneth E. Rosenzweig, Joe Yujiao Chang, Richard M. Gewanter, Mark E. Ginsburg, Feng-Ming Kong, Brian E. Lally, Gregory M. Videtic, Benjamin Movsas. (2011) ACR Appropriateness Criteria® Postoperative Adjuvant Therapy in Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 34:5, 537-544
CrossRef19
Takeshi Hanagiri, Masakazu Sugaya, Masaru Takenaka, Sohich Oka, Tetsuro Baba, Yoshiki Shigematsu, Yoshika Nagata, Hidehiko Shimokawa, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto, Fumihiro Tanaka. (2011) Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 74:1, 112-117
CrossRef20
Melissa H. Coleman, Raphael Bueno. (2011) Role of Adjuvant Chemotherapy in NSCLC (Stages I to III). Surgical Oncology Clinics of North America 20:4, 757-767
CrossRef21
Jaafar Bennouna, Hélène Senellart, Sandrine Hiret, Nathalie Vaissiere, Jean-Yves Douillard. (2011) Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 74:1, 30-34
CrossRef22
John M. Varlotto, Laura Nyshel Medford-Davis, Abram Recht, John C. Flickinger, Eric Schaefer, Malcolm M. DeCamp. (2011) Failure Rates and Patterns of Recurrence in Patients With Resected N1 Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 81:2, 353-359
CrossRef23
T. Brodowicz, T. Ciuleanu, J. Crawford, M. Filipits, J. R. Fischer, V. Georgoulias, C. Gridelli, F. R. Hirsch, J. Jassem, P. Kosmidis, M. Krzakowski, C. Manegold, J. L. Pujol, R. Stahel, N. Thatcher, J. Vansteenkiste, C. Minichsdorfer, S. Zochbauer-Muller, R. Pirker, C. C. Zielinski, . (2011) Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology
CrossRef24
Bernhard C. Danner, Timo Hellms, Klaus Jung, Bastian Gunawan, Vassilios Didilis, Laszlo Füzesi, Friedrich A. Schöndube. (2011) Prognostic Value of Chromosomal Imbalances in Squamous Cell Carcinoma and Adenocarcinoma of the Lung. The Annals of Thoracic Surgery 92:3, 1038-1043
CrossRef25
Thierry Le Chevalier. (2011) Management of early-stage non-small-cell lung cancer (NSCLC). European Journal of Cancer 47, S292-S293
CrossRef26
Rohit Lal, Deborah Enting, Hartmut Kristeleit. (2011) Systemic treatment of non-small-cell lung cancer. European Journal of Cancer 47, S375-S377
CrossRef27
Sofia R. Gameiro, Jorge A. Caballero, Jack P. Higgins, David Apelian, James W. Hodge. (2011) Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunology, Immunotherapy 60:9, 1227-1242
CrossRef28
Stephen A. Barnett, Valerie W. Rusch, Junting Zheng, Bernard J. Park, Nabil P. Rizk, Gabriel Plourde, Manjit S. Bains, Robert J. Downey, Ronglai Shen, Mark G. Kris. (2011) Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy. Journal of Thoracic Oncology 6:9, 1530-1536
CrossRef29
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef30
Howard West. (2011) The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports 13:4, 280-289
CrossRef31
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef32
Shair Ahmed, Ariel E. Birnbaum, Howard P. Safran, Thomas A. Dipetrillo, Bassam I. Aswad, Neal E. Ready, Thomas Ng. (2011) Pathologic Response After Neoadjuvant Carboplatin and Weekly Paclitaxel for Early-Stage Lung Cancer. Journal of Thoracic Oncology 6:8, 1432-1434
CrossRef33
Thomas E. Stinchcombe, Jeffery Bogart, Nirmal K. Veeramachaneni, Robert Kratzke, Ramaswamy Govindan. (2011) Annual Review of Advances in Non-small Cell Lung Cancer Research. Journal of Thoracic Oncology 6:8, 1443-1450
CrossRef34
Hyeon-Kyoung Koo, Sang-Man Jin, Chang-Hoon Lee, Hyo-Jeong Lim, Jae-Joon Yim, Young Tae Kim, Seok-Chul Yang, Chul-Gyu Yoo, Sung Koo Han, Joo Hyun Kim, Young-Soo Shim, Young Whan Kim. (2011) Factors associated with recurrence in patients with curatively resected stage I–II lung cancer. Lung Cancer 73:2, 222-229
CrossRef35
Szu-Hua Pan, Yu-Chih Chao, Pei-Fang Hung, Hsuan-Yu Chen, Shuenn-Chen Yang, Yih-Leong Chang, Chen-Tu Wu, Cheng-Chi Chang, Wen-Lung Wang, Wing-Kai Chan, Yi-Ying Wu, Ting-Fang Che, Lu-Kai Wang, Chien-Yu Lin, Yung-Chie Lee, Min-Liang Kuo, Chau-Hwang Lee, Jeremy J.W. Chen, Tse-Ming Hong, Pan-Chyr Yang. (2011) The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. Journal of Clinical Investigation 121:8, 3189-3205
CrossRef36
Takaaki Yamada, Nobuaki Egashira, Hiroyuki Watanabe, Kenichiro Nagata, Takahisa Yano, Toshiharu Nonaka, Ryozo Oishi. (2011) Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention. Supportive Care in Cancer
CrossRef37
Shannon Otsuka, Alexander C. Klimowicz, Karen Kopciuk, Stephanie K. Petrillo, Mie Konno, Desiree Hao, Huong Muzik, Erin Stolte, William Boland, Don Morris, Anthony M. Magliocco, D. Gwyn Bebb. (2011) CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:7, 1169-1178
CrossRef38
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menis, Silvia Novello, Emilio Bria. (2011) Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer 73:1, 78-88
CrossRef39
Shu-hai Li, Hui Tian, Wei-ming Yue, Lin Li, Wen-jun Li, Zhi-tao Chen, Wen-si Hu, Ying-chao Zhu, Lei Qi. (2011) Overexpression of Metastasis-Associated Protein 1 is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early-Stage Non-Small Cell Lung Cancer. Annals of Surgical Oncology 18:7, 2048-2056
CrossRef40
Yu Qin, Geurt Stokman, Kuan Yan, Sreenivasa Ramaiahgari, Fons Verbeek, Marjo de Graauw, Bob van de Water, Leo S. Price. (2011) Cyclic AMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. British Journal of Pharmacologyno-no
CrossRef41
Jessica S. Donington, Yolonda L. Colson. (2011) Sex and Gender Differences in Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 23:2, 137-145
CrossRef42
A. T. Shaw, M. M. Winslow, M. Magendantz, C. Ouyang, J. Dowdle, A. Subramanian, T. A. Lewis, R. L. Maglathin, N. Tolliday, T. Jacks. (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proceedings of the National Academy of Sciences 108:21, 8773-8778
CrossRef43
Raymond U. Osarogiagbon, Jeffrey W. Allen, Aamer Farooq, Allen Berry, Thomas O'Brien. (2011) Pathologic Lymph Node Staging Practice and Stage-Predicted Survival After Resection of Lung Cancer. The Annals of Thoracic Surgery 91:5, 1486-1492
CrossRef44
Prunella Blinman, Sue-Anne McLachlan, Anna K. Nowak, Vlatka M. Duric, Chris Brown, Gavin Wright, Michael Millward, Kwun Fong, Martin R. Stockler. (2011) Lung cancer clinicians’ preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer 72:2, 213-218
CrossRef45
T. Reiman, R. Lai, A. S. Veillard, E. Paris, J. C. Soria, R. Rosell, M. Taron, S. Graziano, R. Kratzke, L. Seymour, F. A. Shepherd, J. P. Pignon, P. Seve, . (2011) Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Annals of Oncology
CrossRef46
Marcy Winget, John Fleming, Xue Li, Zhiwei Gao, Charles Butts. (2011) Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Lung Cancer 72:1, 52-58
CrossRef47
Yan Shi, Li Chen, Jie Li, Ya-Li Lv, Qiong Sun, Ling-Xiong Wang, Shun-Chang Jiao. (2011) Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumor Biology 32:2, 381-390
CrossRef48
Sameer K. Nath, Ajay P. Sandhu, Daniel Kim, Anjali Bharne, Polly D. Nobiensky, Joshua D. Lawson, Mark Fuster, Lyudmila Bazhenova, William Y. Song, Arno J. Mundt. (2011) Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiotherapy and Oncology 99:1, 12-17
CrossRef49
Ari VanderWalde, Sumanta Kumar Pal, Karen L. Reckamp. (2011) Management of non-small-cell lung cancer in the older adult. Maturitas 68:4, 311-321
CrossRef50
Sanghui Park, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Junshik Hong, Eun Kyung Cho. (2011) Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:1, 100-107
CrossRef51
Joseph M. Pepek, Junzo P. Chino, Lawrence B. Marks, Thomas A. DʼAmico, David S. Yoo, Mark W. Onaitis, Neal E. Ready, Jessica L. Hubbs, Jessamy Boyd, Chris R. Kelsey. (2011) How Well Does the New Lung Cancer Staging System Predict for Local/Regional Recurrence After Surgery?. Journal of Thoracic Oncology 6:4, 757-761
CrossRef52
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef53
Sacha I Rothschild, Oliver Gautschi, Primo N Lara, Philip C Mack, David R Gandara. (2011) Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Current Opinion in Oncology 23:2, 150-157
CrossRef54
Mara B. Antonoff, Jonathan D'Cunha. (2011) The Coming of Age of Molecular Tumor Profiling. Seminars in Thoracic and Cardiovascular Surgery 23:1, 8-9
CrossRef55
Yelena Y. Janjigian, Bernard J. Park, Maureen F. Zakowski, Marc Ladanyi, William Pao, Sandra P. DʼAngelo, Mark G. Kris, Ronglai Shen, Junting Zheng, Christopher G. Azzoli. (2011) Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology 6:3, 569-575
CrossRef56
B. Besse, C. Massard, V. Haddad, F. Andre, A. Dunant, R. Pirker, K. A. Olaussen, E. Brambilla, P. Fouret, J. C. Soria. (2011) ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of Oncology 22:3, 575-581
CrossRef57
Sandra P. D’Angelo, Bernard Park, Christopher G. Azzoli, Mark G. Kris, Valerie Rusch, Marc Ladanyi, Maureen F. Zakowski. (2011) Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. The Journal of Thoracic and Cardiovascular Surgery 141:2, 476-480
CrossRef58
Jin Gu Lee, Byoung Chul Cho, Mi Kyung Bae, Chang Young Lee, In Kyu Park, Dae Joon Kim, Kyung Young Chung. (2011) Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer. The Annals of Thoracic Surgery 91:2, 344-348
CrossRef59
David J. Stewart, Carmen Behrens, Jack Roth, Ignacio I. Wistuba. (2011) Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer. Lung Cancer 71:2, 217-223
CrossRef60
Meiju Ji, Haixia Guan, Cuixia Gao, Bingyin Shi, Peng Hou. (2011) Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 11:1, 147
CrossRef61
Ming-Sound Tsao, Akira Sakurada, Keyue Ding, Sarit Aviel-Ronen, Olga Ludkovski, Ni Liu, Aurélie Le Maître, David Gandara, David H. Johnson, James R. Rigas, Lesley Seymour, Frances A. Shepherd. (2011) Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 139-147
CrossRef62
Motoki Yano, Hidefumi Sasaki, Satoru Moriyama, Osamu Kawano, Yu Hikosaka, Yoshitaka Fujii. (2011) Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer. Annals of Thoracic and Cardiovascular Surgery 17:1, 58-62
CrossRef63
Han Suk Ryu, Xianhua Xu, Hyojin Kim, Jong-Suk Lee, Sanghoon Jheon, Jin-Haeng Chung. (2011) ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. The Korean Journal of Pathology 45:1, 45
CrossRef64
Mi Young Kim, Hong-Gyun Wu, Hak Jae Kim, Dae-Seog Heo, Young Whan Kim, Dong-Wan Kim, Se-Hoon Lee, Joo Hyun Kim, Young Tae Kim, Chang-Hyun Kang. (2011) Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection. The Journal of the Korean Society for Therapeutic Radiology and Oncology 29:1, 44
CrossRef65
Masahiko Harada, Tai Hato, Hirotoshi Horio. (2011) Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 48-54
CrossRef66
Alex Chang. (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:1, 3-10
CrossRef67
Yoshio Okano, Hiroyuki Hino, Mitsuteru Yoshida, Nobuo Hatakeyama, Tsutomu Shinohara, Fumitaka Ogushi. (2011) Safety of Adjuvant Chemotherapy with Carboplatin and Weekly Paclitaxel for Pathological Stage IB-IIIB Non-small Cell Lung Cancer. Haigan 51:3, 165-170
CrossRef68
T. Hanagiri, M. Takenaka, S. Oka, Y. Shigematsu, Y. Nagata, H. Shimokawa, H. Uramoto, S. Yamada, F. Tanaka. (2011) Prognostic Significance of Lymphovascular Invasion for Patients with Stage I Non-Small Cell Lung Cancer. European Surgical Research 47:4, 211-217
CrossRef69
Guanchao Jiang, Fan Yang, Xiao Li, Jun Liu, Jianfeng Li, Hui Zhao, Yun Li, Jun Wang. (2011) Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer. World Journal of Surgical Oncology 9:1, 170
CrossRef70
, Noriyasu Usami, Kohei Yokoi, Yoshinori Hasegawa, Hiroyuki Taniguchi, Joe Shindo, Masashi Yamamoto, Ryujiro Suzuki, Kazuyoshi Imaizumi, Masashi Kondo, Kaoru Shimokata. (2010) Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. International Journal of Clinical Oncology 15:6, 583-587
CrossRef71
J.M. Naranjo Gómez, J.J. Gómez Román. (2010) Behaviour and survival of high-grade neuroendocrine carcinomas of the lung. Respiratory Medicine 104:12, 1929-1936
CrossRef72
Farzan Siddiqui, Andre A Konski, Benjamin Movsas. (2010) Quality-of-life concerns in lung cancer patients. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, 667-676
CrossRef73
Giuseppe Bronte, Sergio Rizzo, Laura La Paglia, Vincenzo Adamo, Sergio Siragusa, Corrado Ficorella, Daniele Santini, Viviana Bazan, Giuseppe Colucci, Nicola Gebbia, Antonio Russo. (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews 36, S21-S29
CrossRef74
Jessica L. Hubbs, Jessamy A. Boyd, Donna Hollis, Junzo P. Chino, Mert Saynak, Chris R. Kelsey. (2010) Factors associated with the development of brain metastases. Cancer 116:21, 5038-5046
CrossRef75
Johan F. Vansteenkiste, Frances A. Shepherd. (2010) The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices. Journal of Thoracic Oncology 5:11, 1724-1725
CrossRef76
José Manuel Trigo Pérez, Pilar Garrido López, Enriqueta Felip Font, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical and Translational Oncology 12:11, 735-741
CrossRef77
Keiju Aokage, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai. (2010) Subcarinal lymph node in upper lobe non-small cell lung cancer patients: Is selective lymph node dissection valid?. Lung Cancer 70:2, 163-167
CrossRef78
Koji Okudela, Tetsukan Woo, Hitoshi Kitamura. (2010) KRAS gene mutations in lung cancer: Particulars established and issues unresolved. Pathology International 60:10, 651-660
CrossRef79
Sandra Geiger, Marcus Schlemmer, Volker Heinemann, Hans Joachim Stemmler. (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anti-Cancer Drugs 21:9, 799-804
CrossRef80
T. Le Chevalier. (2010) Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?. Annals of Oncology 21:Supplement 7, vii196-vii198
CrossRef81
Masayuki Tanahashi, Hiroshi Niwa, Haruhiro Yukiue, Eriko Suzuki, Hiroshi Haneda, Naoko Yoshii. (2010) Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival. Journal of Thoracic Oncology 5:9, 1376-1381
CrossRef82
Takehito Shukuya, Toshiaki Takahashi, Akihiro Tamiya, Akira Ono, Satoshi Igawa, Yukiko Nakamura, Asuka Tsuya, Haruyasu Murakami, Masahiro Endo, Yasuhisa Ohde, Kazuo Nakagawa, Takehiro Okumura, Haruhiko Kondo, Nobuyuki Yamamoto. (2010) Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons. Medical Oncology 27:3, 932-937
CrossRef83
Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos. (2010) Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports 12:5, 335-348
CrossRef84
Sandra C Tomaszek, Marianne Huebner, Dennis A Wigle. (2010) Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine 4:4, 499-508
CrossRef85
Dandan Yi, Timothy Scott Wiedmann. (2010) Inhalation Adjuvant Therapy for Lung Cancer. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23:4, 181-187
CrossRef86
Ichiro Yoshino, Masafumi Yamaguchi, Koji Yamazaki, Fumihiro Shoji, Motoharu Hamatake, Yoshihiko Maehara. (2010) Surgical outcome of an anatomical resection of clinical stage IA non-small cell lung cancer assisted with a video-thoracoscopy. Surgery Today 40:8, 719-724
CrossRef87
Yu-Chung Wu, Li-Jen Su, Hao-Wei Wang, Chien-Fu Jeff Lin, Wen-Hu Hsu, Teh-Ying Chou, Chi-Ying F. Huang, Chia-Li Lu, Chung-Tsen Hsueh. (2010) Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:8, 1167-1174
CrossRef88
Daniel Morgensztern, Ramaswamy Govindan. (2010) Best of the Month. Journal of Thoracic Oncology 5:8, 1305-1307
CrossRef89
Mert Saynak, Daniel S. Higginson, David E. Morris, Lawrence B. Marks. (2010) Current Status of Postoperative Radiation for Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology 20:3, 192-200
CrossRef90
Peter Tcherveniakov, Eirik Svennevik, Richard Milton, Kostas Papagiannopoulos. (2010) Diagnostic and Therapeutic Applications of Video-Assisted Mediastinoscopy. Clinical Pulmonary Medicine 17:4, 177-183
CrossRef91
Jenn-Yu Wu, Chih-Hsin Yang, Ya-Chieh Hsu, Chong-Jen Yu, Shih-Han Chang, Jin-Yuan Shih, Pan-Chyr Yang. (2010) Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:4, 257-263
CrossRef92
Clifford G. Robinson, Jeffrey D. Bradley. (2010) The Treatment of Early-Stage Disease. Seminars in Radiation Oncology 20:3, 178-185
CrossRef93
Takeshi Hanagiri, Tetsuro Baba, Tetsuya So, Manabu Yasuda, Masakazu Sugaya, Kenji Ono, Tomoko So, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto. (2010) Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:6, 825-829
CrossRef94
I.A. Adamietz, N. Niederle. (2010) Lungenkarzinom. Der Onkologe 16:6, 615-628
CrossRef95
Hai-bo Sun, Si-yu Wang, Wei Ou, Bin-bin Zhang, Hua Yang, Qin Fang. (2010) The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Lung Cancer 68:3, 403-408
CrossRef96
Bingwen Zou, Yong Xu, Tao Li, Wenhui Li, Bangxian Tang, Lin Zhou, Lu Li, Yongmei Liu, Jiang Zhu, Meijuan Huang, Jin Wang, Li Ren, Youlin Gong, Guowei Che, Lunxu Liu, Mei Hou, You Lu. (2010) A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Nodal Disease. International Journal of Radiation Oncology*Biology*Physics 77:2, 321-328
CrossRef97
Stephen L. Graziano, Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, Arkadiusz Z. Dudek, Everett E. Vokes, Mark R. Green. (2010) Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:6, 810-817
CrossRef98
Masayoshi Inoue, Masato Minami, Noriyoshi Sawabata, Tomoki Utsumi, Yoshihisa Kadota, Norihisa Shigemura, Meinoshin Okumura. (2010) Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 37:6, 1445-1449
CrossRef99
Elizabeth M. Blanchard, Konstantinos Arnaoutakis, Paul J. Hesketh. (2010) Lung Cancer in Octogenarians. Journal of Thoracic Oncology 5:6, 909-916
CrossRef100
Wei Ou, Hai-bo Sun, Xiong Ye, Bin-bin Zhang, Hua Yang, Qin Fang, Pan Li, Si-yu Wang. (2010) Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef101
Masafumi Yamaguchi, Sadanori Takeo, Ryuichi Suemitsu, Hironori Matsuzawa. (2010) Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:1, 107-112
CrossRef102
L. Crino, W. Weder, J. van Meerbeeck, E. Felip, . (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v103-v115
CrossRef103
Navneet Singh, Amanjit Bal, Ashutosh N Aggarwal, Ashim Das, Digambar Behera. (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncology 6:5, 741-767
CrossRef104
Tommaso De Pas, Sara Raimondi, Giuseppe Pelosi, Lorenzo Spaggiari, Fillipo De Braud, Giulia Veronesi, Patrick Maisonneuve. (2010) A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. Acta Oncologica 49:4, 480-484
CrossRef105
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef106
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, M. Aapro. (2010) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Annals of Oncology 21:4, 692-706
CrossRef107
Gregory P Kalemkerian. (2010) Adjuvant therapy for non-small-cell lung cancer. The Lancet 375:9722, 1230-1231
CrossRef108
Kazuhito Funai, Kazuya Takamochi, Toru Itaya, Takahiro Mochizuki, Toru Nakamura, Futoru Toyoda, Kim Yong-Il, Kazuyoshi Sasaki, Shigeru Momiki, Tsuyoshi Takahashi, Hiroshi Neyatani, Kazuya Suzuki. (2010) Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer. Lung Cancer 68:1, 78-83
CrossRef109
M. Mohr, T. Kessler, U. Krug, P. Hoffknecht, L.H. Schmidt, K. Wiebe, W.E. Berdel, R. Wiewrodt. (2010) Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 24:2, 97-104
CrossRef110
Masayuki Nakao, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai. (2010) Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients. Journal of Thoracic Oncology 5:4, 504-509
CrossRef111
(2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. The Lancet 375:9722, 1267-1277
CrossRef112
Heather-Jane Au, Jolie Ringash, Michael Brundage, Michael Palmer, Harriet Richardson, Ralph M Meyer. (2010) Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, 119-128
CrossRef113
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef114
Jared Weiss, Beth Eaby, James Stevenson, John Kucharczuk, Joel Cooper, Larry Kaiser, Joseph Shrager, Ramesh Rengan, Corey Langer, Tracey Evans. (2010) Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef115
Tony Dhillon, Francesco A. Mauri, Guido Bellezza, Lucio Cagini, Mattia Barbareschi, Bernard V. North, Michael J. Seckl. (2010) Overexpression of the Mammalian Target of Rapamycin. Journal of Thoracic Oncology 5:3, 314-319
CrossRef116
Paul Wheatley-Price, Aurélie Le Maître, Keyue Ding, Natasha Leighl, Vera Hirsh, Lesley Seymour, Andrea Bezjak, Frances A. Shepherd. (2010) The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials. Journal of Thoracic Oncology1
CrossRef117
Youngil Koh, Bogun Jang, Sae-Won Han, Tae-Min Kim, Do-Youn Oh, Se-Hoon Lee, Chang Hyun Kang, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Young Tae Kim, Tae-You Kim, Young-Whan Kim, Joo Hyun Kim, Dae Seog Heo, Yung-Jue Bang. (2010) Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:3, 320-325
CrossRef118
Zhannat Nurgalieva, Rui Xia, Chih-Chin Liu, Keith Burau, Dale Hardy, Xianglin L Du. (2010) Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer. American Journal of Therapeutics 17:2, 148-158
CrossRef119
Sebastian Dango, Xiao Tao Wang, Monika Gold, Beatrix Cucuruz, Christoph A. Klein, Bernward Passlick, Wulf Sienel. (2010) Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer. Lung Cancer 67:3, 290-295
CrossRef120
Xu-Wei Cai, Lu-Ying Xu, Li Wang, James A. Hayman, Andrew C. Chang, Allan Pickens, Kemp B. Cease, Mark B. Orringer, Feng-Ming Kong. (2010) Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Non–Small-Cell Lung Cancer Treated With Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 76:4, 1100-1105
CrossRef121
R. Velasco, J. Bruna. (2010) Neuropatía inducida por quimioterapia: un problema no resuelto. Neurología 25:2, 116-131
CrossRef122
R. Velasco, J. Bruna. (2010) Chemotherapy-induced peripheral neuropathy: An unresolved issue. Neurología (English Edition) 25:2, 116-131
CrossRef123
Jessamy A. Boyd, Jessica L. Hubbs, Dong W. Kim, Donna Hollis, Lawrence B. Marks, Chris R. Kelsey. (2010) Timing of Local and Distant Failure in Resected Lung Cancer. Journal of Thoracic Oncology 5:2, 211-214
CrossRef124
Pascal Sève, Tony Reiman, Charles Dumontet. (2010) The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:2, 136-143
CrossRef125
Tokujiro Yano, Koji Yamazaki, Riichiroh Maruyama, Shoji Tokunaga, Fumihiro Shoji, Hidefumi Higashi, Sadanori Takeo, Yukito Ichinose, Yoshihiko Maehara. (2010) Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer—LOGIK 0601 study. Lung Cancer 67:2, 184-187
CrossRef126
Hyeong Su Kim, Yeon Hee Park, Jeeyun Lee, Jin-Seok Ahn, Jinkook Kim, Young Mog Shim, Jung Han Kim, Keunchil Park, Joungho Han, Myung-Ju Ahn. (2010) Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 116:3, 676-685
CrossRef127
Jean-Yves Douillard, Hélène Tribodet, Delphine Aubert, Frances A. Shepherd, Rafael Rosell, Keyue Ding, Anne-Sophie Veillard, Lesley Seymour, Thierry Le Chevalier, Stephen Spiro, Richard Stephens, Jean Pierre Pignon. (2010) Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:2, 220-228
CrossRef128
Kazuhito Funai, Takahiro Mochizuki, Shigeru Momiki. (2010) Dose Escalation Study of Adjuvant Chemotherapy with Cisplatin Plus Vinorelbine in Japanese Patients with Completely Resected Non-small Cell Lung Cancer. Haigan 50:2, 136-140
CrossRef129
Szu-Hua Pan, Yu-Chih Chao, Hsuan-Yu Chen, Pei-Fang Hung, Pei-Ying Lin, Chung-Wu Lin, Yih-Leong Chang, Chen-Tu Wu, Yung-Chie Lee, Shuenn-Chen Yang, Tse-Ming Hong, Pan-Chyr Yang. (2010) Long form collapsin response mediator protein-1 (LCRMP-1) expression is associated with clinical outcome and lymph node metastasis in non-small cell lung cancer patients. Lung Cancer 67:1, 93-100
CrossRef130
Carol C. Wu, Bruce M. Barack. 2010. Evaluation and Management of the Solitary Pulmonary Nodule. , 191-196.
CrossRef131
Jun Wu, Cheng-ping Hu, Qi-hua Gu, Ye-peng Li, Min Song. (2010) Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacologica Sinica 31:1, 93-101
CrossRef132
Hyung Koo Kang, Sung Gun Cho, Hye-Min Lee, Sung Woon Park, Byung Ook Lee, Jae Hee Lee, Bo Min Kim, In Won Park. (2010) Cell Differentiation Might Predict the Recurrence in Surgically Resected Non-Small Cell Lung Carcinoma. Tuberculosis and Respiratory Diseases 68:1, 10
CrossRef133
Haruaki Hino, Shingo Ikeda, Ryoji Kawano, Tatsuhiro Hoshino, Toshiya Yokota, Enjo Hata. (2010) Lung cancer resection and adjuvant chemotherapy in a chronic renal failure patient. The Journal of the Japanese Association for Chest Surgery 24:5, 873-878
CrossRef134
Hisashi Saji, Masahiro Tsuboi, Jun Matsubayashi, Kuniharu Miyajima, Yoshihisa Shimada, Kentaro Imai, Yasubumi Kato, Jitsuo Usuda, Naohiro Kajiwara, Osamu Uchida, Tatsuo Ohira, Takashi Hirano, Kiyoshi Mukai, Harubumi Kato, Norihiko Ikeda. (2010) Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anti-Cancer Drugs 21:1, 89-93
CrossRef135
Takaaki Yamada, Nobuaki Egashira, Maiko Imuta, Takahisa Yano, Yui Yamauchi, Hiroyuki Watanabe, Ryozo Oishi. (2010) Role of oxidative stress in vinorelbine-induced vascular endothelial cell injury. Free Radical Biology and Medicine 48:1, 120-127
CrossRef136
Kohei Yokoi, Tetsuya Mitsudomi, Haruhiko Kondo, Hiroshi Niwa, Kazuo Yoshida, Shinichiro Ohta, Kikuo Shigemitsu, Motoki Yano, Toru Tanaka, Motoshi Takao. (2010) Adjuvant Chemotherapy in Patients with Completely Resected Lung Cancer: Investigation of the Current Situation After Publication of the Second Edition of Clinical Practice Guidelines for Lung Cancer. Haigan 50:3, 280-286
CrossRef137
Takeshi Hanagiri, Tetsuro Baba, Yoshinobu Ichiki, Manabu Yasuda, Masakazu Sugaya, Kenji Ono, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto. (2010) Sleeve lobectomy for patients with non-small cell lung cancer. International Journal of Surgery 8:1, 39-43
CrossRef138
Dale Hardy, Janice N. Cormier, Yan Xing, Chih-Chin Liu, Rui Xia, Xianglin L. Du. (2010) Chemotherapy-Associated Toxicity in a Large Cohort of Elderly Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 90-98
CrossRef139
Fumihiro Tanaka, Hiromi Wada, Masakazu Fukushima. (2010) UFT and S-1 for treatment of primary lung cancer. General Thoracic and Cardiovascular Surgery 58:1, 3-13
CrossRef140
Yuki Yamane, Genichiro Ishii, Koichi Goto, Motohiro Kojima, Masayuki Nakao, Yoshihisa Shimada, Yutaka Nishiwaki, Kanji Nagai, Hirotsugu Kohrogi, Atsushi Ochiai. (2010) A Novel Histopathological Evaluation Method Predicting the Outcome of Non-small Cell Lung Cancer Treated by Neoadjuvant Therapy. Journal of Thoracic Oncology 5:1, 49-55
CrossRef141
MyChau T. Nguyen, Irim Y. Virk, Lita Chew, J. Lee Villano. (2009) Extended use dexamethasone-associated posterior reversible encephalopathy syndrome with cisplatin-based chemotherapy. Journal of Clinical Neuroscience 16:12, 1688-1690
CrossRef142
Emilio Bria, Michele Milella, Isabella Sperduti, Gabriele Alessandrini, Paolo Visca, Felicita Corzani, Diana Giannarelli, Virna Cerasoli, Federica Cuppone, Fabiana Letizia Cecere, Antonio Marchetti, Rocco Sacco, Felice Mucilli, Sara Malatesta, Luigi Guetti, Luca Vitale, Anna Ceribelli, Massimo Rinaldi, Edmondo Terzoli, Francesco Cognetti, Francesco Facciolo. (2009) A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer 66:3, 365-371
CrossRef143
Sacha Rothschild, O. Gautschi. (2009) Non-small cell lung cancer – ASCO 2009. memo - Magazine of European Medical Oncology 2:4, 202-205
CrossRef144
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Cancer Reviews 3:1, 9-18
CrossRef145
Lisa K. Hicks, Matthew C. Cheung, Keyue Ding, Baktiar Hasan, Lesley Seymour, Aurélie Le Maître, Natasha B. Leighl, Frances A. Shepherd. (2009) Venous thromboembolism and nonsmall cell lung cancer. Cancer 115:23, 5516-5525
CrossRef146
Chikuma Hamada, Masahiro Tsuboi, Mitsuo Ohta, Shigefumi Fujimura, Ken Kodama, Munehisa Imaizumi, Hiromi Wada. (2009) Effect of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival in Patients with Stage IA Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1511-1516
CrossRef147
Christophe Massard, Pierre Tran Ba Loc, Vincent Haddad, Jean-Pierre Pignon, Philippe Girard, Isabelle Monnet, Jean Trédaniel, Benjamin Besse, Jean-Charles Soria. (2009) Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. Journal of Thoracic Oncology 4:12, 1504-1510
CrossRef148
Ayesha S. Bryant, Robert J. Cerfolio. (2009) Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon. Indian Journal of Surgery 71:6, 310-316
CrossRef149
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef150
Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Osamu Kawashima, Yosuke Kamide, Tamotsu Ishizuka, Yoshikatsu Kanai, Takashi Nakajima, Masatomo Mori. (2009) CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases. Annals of Surgical Oncology 16:12, 3473-3481
CrossRef151
Sameer Desai, Edgar Ben-Josef, Kent A. Griffith, Diane Simeone, Joel K. Greenson, Isaac R. Francis, Janet Hampton, Lisa Colletti, Alfred E. Chang, Theodore S. Lawrence, Mark M. Zalupski. (2009) Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer. International Journal of Radiation Oncology*Biology*Physics 75:5, 1450-1455
CrossRef152
Ho Yun Lee, Joungho Han, Kyung Soo Lee, Ji Hyun Koo, Sun Young Jeong, Byung-Tae Kim, Young-Seok Cho, Young Mog Shim, Jhingook Kim, Kwanmien Kim, Yong Soo Choi. (2009) Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 66:3, 379-385
CrossRef153
Chris R. Kelsey, Lawrence B. Marks, Donna Hollis, Jessica L. Hubbs, Neal E. Ready, Thomas A. D'Amico, Jessamy A. Boyd. (2009) Local recurrence after surgery for early stage lung cancer. Cancer 115:22, 5218-5227
CrossRef154
Benjamin E. Haithcock, Thomas E. Stinchcombe, Mark A. Socinski. (2009) Treatment of Surgically Resectable Non–Small-Cell Lung Cancer in Elderly Patients. Clinical Lung Cancer 10:6, 405-409
CrossRef155
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Lung Cancer 10:6, 395-404
CrossRef156
Eric Lim, Grace Harris, Amit Patel, Iki Adachi, Lyn Edmonds, Fujian Song. (2009) Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:11, 1380-1388
CrossRef157
Hajime Maeda, Shimao Fukai, Akihide Matsumura, Osamu Kawashima, Takehiro Watanabe, Takeshi Yamanda, Kan Okabayashi, Yuka Fujita, Atsuhisa Tamura, Masaaki Kawahara. (2009) Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer. General Thoracic and Cardiovascular Surgery 57:11, 599-604
CrossRef158
Dale Hardy, Rui Xia, Chih-Chin Liu, Janice N. Cormier, Zhannat Nurgalieva, Xianglin L. Du. (2009) Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients. Cancer 115:20, 4807-4818
CrossRef159
Apurva Patel, Masaki Anraku, Gail E. Darling, Frances A. Shepherd, Andrew F. Pierre, Thomas K. Waddell, Shaf Keshavjee, Marc de Perrot. (2009) Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies. The Journal of Thoracic and Cardiovascular Surgery 138:4, 843-848
CrossRef160
Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Takashi Nakajima, Masatomo Mori. (2009) Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 66:1, 120-126
CrossRef161
Michaela J Higgins, David S Ettinger. (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy 9:10, 1365-1378
CrossRef162
Linda E Coate, Thomas John, Ming-Sound Tsao, Frances A Shepherd. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. The Lancet Oncology 10:10, 1001-1010
CrossRef163
Boone Goodgame, Thomas E. Stinchcombe, George Simon, Antoinette Wozniak, Ramaswamy Govindan. (2009) Recent Advances in Lung Cancer. Journal of Thoracic Oncology 4:10, 1293-1300
CrossRef164
Chang-Qi Zhu, Melania Pintilie, Thomas John, Dan Strumpf, Frances A. Shepherd, Sandy D. Der, Igor Jurisica, Ming-Sound Tsao. (2009) Understanding Prognostic Gene Expression Signatures in Lung Cancer. Clinical Lung Cancer 10:5, 331-340
CrossRef165
Howard West, Rogerio Lilenbaum, David Harpole, Antoinette Wozniak, Lecia Sequist. (2009) Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:Supplement 2, S1029-S1039
CrossRef166
Tetsukan Woo, Koji Okudela, Takuya Yazawa, Nobuyuki Wada, Nobuo Ogawa, Naoki Ishiwa, Michihiko Tajiri, Yasushi Rino, Hitoshi Kitamura, Munetaka Masuda. (2009) Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 65:3, 355-362
CrossRef167
Satoshi Hashizume, Takeshi Nagayasu, Tomayoshi Hayashi, Shigekazu Hidaka, Tomoshi Tsuchiya, Tsutomu Tagawa, Naoya Yamasaki, Katsuro Furukawa, Keitaro Matsumoto, Takuro Miyazaki. (2009) Accuracy and prognostic impact of a vessel invasion grading system for stage IA non-small cell lung cancer. Lung Cancer 65:3, 363-370
CrossRef168
Christine E. Hill-Kayser, Carolyn Vachani, Margaret K. Hampshire, Linda A. Jacobs, James M. Metz. (2009) Utilization of Internet-Based Survivorship Care Plans by Lung Cancer Survivors. Clinical Lung Cancer 10:5, 347-352
CrossRef169
Christian Manegold, Gerald Schmid-Bindert, Lothar R Pilz. (2009) Pemetrexed for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:9, 1195-1209
CrossRef170
Edgardo S Santos, Cesar A Perez, Luis E Raez. (2009) How is gene-expression profiling going to challenge the future management of lung cancer?. Future Oncology 5:6, 827-835
CrossRef171
Arkadiusz Z. Dudek, Krzysztof Lesniewski-Kmak, Timothy Larson, Konstantin Dragnev, Rachel Isaksson, Vinita Gupta, Michael A. Maddaus, Robert A. Kratzke. (2009) Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:8, 969-975
CrossRef172
Jared Weiss, Corey Langer. (2009) NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Current Treatment Options in Oncology 10:3-4, 180-194
CrossRef173
Ana Belén Custodio, José Luis González-Larriba, Jana Bobokova, Antonio Calles, Rafael Álvarez, Eugenio Cuadrado, Aranzazu Manzano, Eduardo Díaz-Rubio. (2009) Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:7, 891-910
CrossRef174
Lina Carvalho, António Silva, Cláudia Andrade, Cláudia Barroso, Cláudia Farinha, José Carlos Fernandes, Raquel Landeiro. (2009) Os genes ERCC1 e RRM1 no carcinoma broncopulmonar. Revista Portuguesa de Pneumologia (English Edition) 15:4, 683-696
CrossRef175
Hisao Imai, Kyoichi Kaira, Noboru Oriuchi, Noriko Yanagitani, Noriaki Sunaga, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori. (2009) L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 54:7, 804-813
CrossRef176
Takuro Kometani, Ichiro Yoshino, Naoko Miura, Hiroshi Okazaki, Taro Ohba, Tomoyoshi Takenaka, Fumihiro Shoji, Tokujiro Yano, Yoshihiko Maehara. (2009) Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Letters 278:1, 27-33
CrossRef177
Marcy Winget, Jennifer Stanger, Zhiwei Gao, Charles Butts. (2009) Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada. Journal of Thoracic Oncology 4:5, 629-634
CrossRef178
Shun-ichi Watanabe, Hisao Asamura. (2009) Lymph Node Dissection for Lung Cancer. Journal of Thoracic Oncology 4:5, 652-657
CrossRef179
G. D'Addario, E. Felip, . (2009) Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv68-iv70
CrossRef180
Rodney J. Landreneau. (2009) Invited Commentary. The Annals of Thoracic Surgery 87:4, 1028-1029
CrossRef181
Marshall W. Pitz, Grace Musto, Alain A. Demers, Erich V. Kliewer, Srisala Navaratnam. (2009) Survival and Treatment Pattern of Non-small Cell Lung Cancer Over 20 Years. Journal of Thoracic Oncology 4:4, 492-498
CrossRef182
Rossana Berardi, Lorena Verdecchia, Marzia Di Pietro Paolo, Riccardo Giampieri, Mario Scartozzi, Chiara Pierantoni, Maristella Bianconi, Paola Mazzanti, Stefano Cascinu. (2009) Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology 69:3, 223-236
CrossRef183
Hiroshi Takita, Kyu H. Shin, Andrew Y. Soh, Won S. Yi, Greg Wilding. (2009) Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?). Lung Cancer 63:3, 387-392
CrossRef184
Randeep Sangha, Primo N Lara, Philip C Mack, David R Gandara. (2009) Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Current Opinion in Oncology 21:2, 116-123
CrossRef185
Takeo Ito, Genichiro Ishii, Kanji Nagai, Tatsuya Nagano, Masakazu Kojika, Yukinori Murata, Naho Atsumi, Yutaka Nishiwaki, Eishi Miyazaki, Toshihide Kumamoto, Atsushi Ochiai. (2009) Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 63:3, 418-424
CrossRef186
John M. Varlotto, Abram Recht, John C. Flickinger, Laura N. Medford-Davis, Ann M. Dyer, Malcolm M. DeCamp. (2009) Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 115:5, 1059-1069
CrossRef187
P. C. Boutros, S. K. Lau, M. Pintilie, N. Liu, F. A. Shepherd, S. D. Der, M.-S. Tsao, L. Z. Penn, I. Jurisica. (2009) Prognostic gene signatures for non-small-cell lung cancer. Proceedings of the National Academy of Sciences 106:8, 2824-2828
CrossRef188
Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori. (2009) Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Science 100:2, 249-254
CrossRef189
Hossein Borghaei, Ranee Mehra, George Simon. (2009) Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Future Oncology 5:1, 19-22
CrossRef190
Kazuhiko Kataoka, Toshiya Fujiwara, Motoki Matsuura, Noritomo Seno. (2009) A Case of Pulmonary Adenocarcinoma Complicated with Methicillin-resistant Staphylococcus Aureus(MRSA) Empyema During Adjuvant Chemotherapy Successfully Treated with Thoracoscopic Debridement and Intrathoracic Lavage. Haigan 49:6, 863-867
CrossRef191
Emilio Bria, Richard J. Gralla, Harry Raftopoulos, Federica Cuppone, Michele Milella, Isabella Sperduti, Paolo Carlini, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2009) Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. Lung Cancer 63:1, 50-57
CrossRef192
Michael C. Cheung, Kara Hamilton, Recinda Sherman, Margaret M. Byrne, Dao M. Nguyen, Dido Franceschi, Leonidas G. Koniaris. (2009) Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients. Annals of Surgical Oncology 16:1, 3-13
CrossRef193
Elaine H. Lim, Shen-Li Zhang, Jia-Liang Li, Wee-See Yap, Tse-Chiang Howe, Bien-Peng Tan, Yong-Shyan Lee, Daniel Wong, Kay-Leong Khoo, Kar-Yin Seto, Lenny Tan, Thirugananam Agasthian, Heng-Nung Koong, John Tam, Christie Tan, Michael Caleb, Alex Chang, Alan Ng, Patrick Tan. (2009) Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 4:1, 12-21
CrossRef194
Yoshiki Hayashi, Hideyuki Kuriyama, Hajime Umezu, Junta Tanaka, Tatsuya Yoshimasu, Tomoko Furukawa, Hiroshi Tanaka, Hiroshi Kagamu, Fumitake Gejyo, Hirohisa Yoshizawa. (2009) Class III β-Tubulin Expression in Tumor Cells is Correlated with Resistance to Docetaxel in Patients with Completely Resected Non-Small-Cell Lung Cancer. Internal Medicine 48:4, 203-208
CrossRef195
Hong In Yoon, Yong Bae Kim, Chang Geol Lee, Ik Jae Lee, Songyih Kim, Jun Won Kim, Joo Hang Kim, Byung Chul Cho, Jin Gu Lee, Kyung Young Chung. (2009) Division of the N2 Stage According to the Multiplicity of the Involved Nodal Stations May be Necessary in the N2-NSCLC Patients Who are Treated with Postoperative Radiotherapy. The Journal of the Korean Society for Therapeutic Radiology and Oncology 27:3, 126
CrossRef196
Hyun Joo Lee, Jisuk Jo, Dae-Soon Son, Jinseon Lee, Yong Soo Choi, Kwhanmien Kim, Young Mog Shim, Jhingook Kim. (2009) Predicting Recurrence Using the Clinical Factors of Patients with Non-small Cell Lung Cancer After Curative Resection. Journal of Korean Medical Science 24:5, 824
CrossRef197
T. Shukuya, T. Takahashi, A. Tamiya, A. Ono, S. Igawa, A. Tsuya, Y. Nakamura, H. Murakami, T. Naito, K. Kaira, M. Endo, N. Yamamoto. (2008) Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study. Japanese Journal of Clinical Oncology 39:3, 158-162
CrossRef198
Yelena Krupitskaya, Billy W. Loo. (2008) Post-Operative Radiation Therapy (PORT) in Completely Resected Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology 9:4-6, 343-356
CrossRef199
George R. Simon. (2008) Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions. Current Treatment Options in Oncology 9:4-6, 300-312
CrossRef200
Tetsuya Mizuno, Genichiro Ishii, Kanji Nagai, Junji Yoshida, Mitsuyo Nishimura, Takahiro Mochizuki, Osamu Kawai, Takahiro Hasebe, Atsushi Ochiai. (2008) Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer 62:3, 302-308
CrossRef201
Nilesh Vora, Karen L. Reckamp. (2008) Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. Seminars in Oncology 35:6, 590-596
CrossRef202
April Scott, Ravi Salgia. (2008) Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomarkers in Medicine 2:6, 577-586
CrossRef203
Tanise Jackson, Mahavir B. Chougule, Nkechi Ichite, Ram R. Patlolla, Mandip Singh. (2008) Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemotherapy and Pharmacology 63:1, 117-126
CrossRef204
Rachel E. Sanborn. (2008) Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?. Current Treatment Options in Oncology 9:4-6, 326-342
CrossRef205
Edgardo S Santos, Aurelio Castrellon, Marcelo Blaya, Luis E Raez. (2008) Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:12, 1913-1929
CrossRef206
Giuseppe Aprile, Ornella Belvedere, Fabio Puglisi. (2008) From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs 19:10, 941-956
CrossRef207
Tallal Younis, Turki Al-Fayea, Kiran Virik, Wojciech Morzycki, Nathalie Saint-Jacques. (2008) Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:11, 1272-1278
CrossRef208
Takayuki Fukui, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Tetsuya Mitsudomi. (2008) Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small cell lung cancers. The Journal of Thoracic and Cardiovascular Surgery 136:5, 1343-1348
CrossRef209
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Marcello Riggi, Patrick Hurteloup, Marc-Andre Mahe. (2008) Impact of Postoperative Radiation Therapy on Survival in Patients With Complete Resection and Stage I, II, or IIIA Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International Journal of Radiation Oncology*Biology*Physics 72:3, 695-701
CrossRef210
M. Pless, F. Gambazzi, P. Stillhart, Th. Lieb, M. Brutsche. (2008) Induction chemotherapy followed by parenchyma-sparing surgery in medically inoperable NSCLC—Results of a feasibility study. Lung Cancer 62:2, 228-235
CrossRef211
Gerold Bepler, K Eric Sommers, Alan Cantor, Xueli Li, Anupama Sharma, Charles Williams, Alberto Chiappori, Eric Haura, Scott Antonia, Tawee Tanvetyanon, George Simon, Coleman Obasaju, Lary A. Robinson. (2008) Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1112-1118
CrossRef212
Ariel Anguiano, Joseph R. Nevins, Anil Potti. (2008) Toward the individualization of lung cancer therapy. Cancer 113:S7, 1760-1767
CrossRef213
Katsuhiro Okuda, Hidefumi Sasaki, Charles Dumontet, Osamu Kawano, Haruhiro Yukiue, Tomoki Yokoyama, Motoki Yano, Yoshitaka Fujii. (2008) Expression of excision repair cross-complementation group 1 and class III β-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62:1, 105-112
CrossRef214
Bedrettin Yıldızeli, Philippe G. Dartevelle, Elie Fadel, Sacha Mussot, Alain Chapelier. (2008) Results of Primary Surgery With T4 Non–Small Cell Lung Cancer During a 25-Year Period in a Single Center: The Benefit is Worth the Risk. The Annals of Thoracic Surgery 86:4, 1065-1075
CrossRef215
Marc M Kueng, Daniel C Betticher. (2008) Treatment in resectable, locally advanced NSCLC: which is the best approach?. Expert Review of Respiratory Medicine 2:5, 655-661
CrossRef216
Nagahiro Saijo. (2008) Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews 34:6, 521-526
CrossRef217
H Kunitoh, H Kato, M Tsuboi, H Asamura, H Tada, K Nagai, T Mitsudomi, T Koike, K Nakagawa, Y Ichinose, M Okada, T Shibata, N Saijo. (2008) A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204). British Journal of Cancer 99:6, 852-857
CrossRef218
S. H. Jeong, H.-W. Lee, J. H. Han, S. Y. Kang, J.-H. Choi, Y. M. Jung, H. Choi, Y. T. Oh, K. J. Park, S. C. Hwang, S. S. Sheen, Y. J. Oh, J. H. Kim, H.-Y. Lim. (2008) Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous Histology. Japanese Journal of Clinical Oncology 38:10, 661-669
CrossRef219
Heather Wakelee, Laveena Chhatwani. (2008) Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 198-203
CrossRef220
V. Westeel, Denis Moro-Sibilot. (2008) Prise en charge oncologique du patient opéré: chimiothérapie adjuvante, surveillance, traitement des rechutes. Oncologie 10:9, 525-528
CrossRef221
Ana Belén Custodio Carretero, José Ángel García Sáenz, José Luis González Larriba, Jana Bobokova, Antonio Calles Blanco, Florentino Hernando Trancho, Beatriz García Paredes, Laura Rodríguez Lajusticia, Eduardo Díaz-Rubio García. (2008) Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clinical and Translational Oncology 10:9, 560-571
CrossRef222
Chao Hui Huang, Michael M. Millenson, Eric J. Sherman, Hossein Borghaei, David M. Mintzer, Roger B. Cohen, Arthur P. Staddon, Judi Seldomridge, Ocn Joseph Treat, Holly Tuttle, Karen J. Ruth, Corey J. Langer. (2008) Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. Journal of Thoracic Oncology 3:9, 1032-1038
CrossRef223
Bruce Montgomery, Philip Lavori, Mark Garzotto, Kelvin Lee, Mary Brophy, Surai Thaneemit-Chen, William Kelly, Joseph Basler, Robert Ringer, Wei Yu, Alice Whittemore, Daniel W. Lin. (2008) Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer. Urology 72:3, 474-480
CrossRef224
Hubert Vesselle, Alexander Salskov, Eric Turcotte, Linda Wiens, Rodney Schmidt, C Diana Jordan, Eric Vallières, Douglas E. Wood. (2008) Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index. Journal of Thoracic Oncology 3:9, 971-978
CrossRef225
Nathalie Saint-Jacques, Daniel Rayson, Turki Al-Fayea, Kiran Virik, Wojciech Morzycki, Tallal Younis. (2008) Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 3:8, 865-870
CrossRef226
Thomas A. D'Amico. (2008) Long-Term Outcomes of Thoracoscopic Lobectomy. Thoracic Surgery Clinics 18:3, 259-262
CrossRef227
L. R. Zacharski, B. K. Chow, P. S. Howes, G. Shamayeva, J. A. Baron, R. L. Dalman, D. J. Malenka, C. K. Ozaki, P. W. Lavori. (2008) Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial. JNCI Journal of the National Cancer Institute 100:14, 996-1002
CrossRef228
Joshua J Filner, David Ost. (2008) Principles of staging as applied to nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine 14:4, 287-291
CrossRef229
Naruyuki Kobayashi, Shinichi Toyooka, Kouichi Ichimura, Junichi Soh, Hiromasa Yamamoto, Keitaro Matsuo, Hiroki Otani, Masaru Jida, Takafumi Kubo, Kazunori Tsukuda, Katsuyuki Kiura, Yoshifumi Sano, Hiroshi Date. (2008) Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung. Journal of Thoracic Oncology 3:7, 704-710
CrossRef230
R.M. Huber. (2008) Therapie des Lungenkarzinoms. Der Pneumologe 5:4, 259-266
CrossRef231
S. Scott Balderson, Thomas A. D’Amico. (2008) Thoracoscopic lobectomy for the management of non-small cell lung cancer. Current Oncology Reports 10:4, 283-286
CrossRef232
M PROVENCIO. (2008) Estado actual del tratamiento adyuvante a la cirugía en los estadios iniciales del cáncer de pulmón no microcítico. Revista Clínica Española 208:6, 302-304
CrossRef233
Vittorio Gebbia. (2008) Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy 9:8, 1321-1337
CrossRef234
Sebastian Dango, Wulf Sienel, Moritz Schreiber, Christian Stremmel, Andreas Kirschbaum, Klaus Pantel, Bernward Passlick. (2008) Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer 60:3, 426-433
CrossRef235
Lecia V. Sequist. (2008) First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation. Journal of Thoracic Oncology 3:Supplement 2, S143-S145
CrossRef236
Jue Wang, Yong Fang Kuo, Jean Freeman, James S. Goodwin. (2008) Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer. Medical Oncology 25:2, 125-132
CrossRef237
M. Dediu. (2008) Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?. memo - Magazine of European Medical Oncology 1:2, 61-65
CrossRef238
Yoshinori Yamashita, Kazuhiko Kataoka, Teruyoshi Ishida, Motoki Matsuura, Noritomo Seno, Hidenori Mukaida, Eiji Miyahara, Yoshihiro Miyata, Riki Okita, Katsuhiko Shimizu, Masanobu Watari, Tsuneo Okumichi, Morihito Okada. (2008) A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:6, 612-616
CrossRef239
M. Filipits, R. Pirker. (2008) Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. memo - Magazine of European Medical Oncology 1:2, 57-60
CrossRef240
Thomas Muley, Timea-Helene Fetz, Hendrik Dienemann, Hans Hoffmann, Felix J.F. Herth, Michael Meister, Werner Ebert. (2008) Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60:3, 408-415
CrossRef241
Penelope A. Bradbury, Frances A. Shepherd. (2008) Immunotherapy for Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S164-S170
CrossRef242
Zhenfa Zhang, Feng Xu, Shengguang Wang, Ni Li, Changli Wang. (2008) Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer. Lung Cancer 60:3, 434-440
CrossRef243
Julian R. Molina, Ping Yang, Stephen D. Cassivi, Steven E. Schild, Alex A. Adjei. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings 83:5, 584-594
CrossRef244
J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, A. A. Adjei. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings 83:5, 584-594
CrossRef245
John M. Varlotto, John C. Flickinger, Abram Recht, Margaret C. Nikolov, Malcolm M. DeCamp. (2008) A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer. Cancer 112:7, 1547-1554
CrossRef246
Ramón San Miguel, Ana María López-González, Eduardo Sanchez-Iriso, Javier Mar, Juan M. Cabasés. (2008) Measuring health-related quality of life in drug clinical trials: is it given due importance?. Pharmacy World & Science 30:2, 154-160
CrossRef247
Alice W.Y. Ng, Stewart Y. Tung, Victy Y.W. Wong. (2008) Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer – report on clinical outcome and dose to critical organs. Radiotherapy and Oncology 87:1, 24-28
CrossRef248
Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, Fortunato Ciardiello. (2008) Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine 2:2, 167-178
CrossRef249
Daniel G. Nicastri, Juan P. Wisnivesky, Virginia R. Litle, Jaime Yun, Cynthia Chin, Francine R. Dembitzer, Scott J. Swanson. (2008) Thoracoscopic lobectomy: Report on safety, discharge independence, pain, and chemotherapy tolerance. The Journal of Thoracic and Cardiovascular Surgery 135:3, 642-647
CrossRef250
Carolyn E. Reed, Amanda Graham, Rana S. Hoda, Andras Khoor, Elizabeth Garrett-Mayer, Michael B. Wallace, Michael Mitas. (2008) A simple two-gene prognostic model for adenocarcinoma of the lung. The Journal of Thoracic and Cardiovascular Surgery 135:3, 627-634
CrossRef251
Paul Wheatley-Price, Frances A Shepherd. (2008) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology 20:2, 162-175
CrossRef252
J Maeda, T Hirano, A Ogiwara, S Akimoto, T Kawakami, Y Fukui, T Oka, Y Gong, R Guo, H Inada, K Nawa, M Kojika, Y Suga, T Ohira, K Mukai, H Kato. (2008) Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. British Journal of Cancer 98:3, 596-603
CrossRef253
Jenifer L. Marks, Stephen Broderick, Qin Zhou, Dhananjay Chitale, Allan R. Li, Maureen F. Zakowski, Mark G. Kris, Valerie W. Rusch, Christopher G. Azzoli, Venkatraman E. Seshan, Marc Ladanyi, William Pao. (2008) Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology 3:2, 111-116
CrossRef254
Pascal Sève, Charles Dumontet. (2008) Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?. The Lancet Oncology 9:2, 168-175
CrossRef255
Thomas E. Stinchcombe, Harry D. Harper, Thomas A. Hensing, Dominic T. Moore, Jeffery M. Crane, James N. Atkins, Ellen M. Willard, Frank C. Detterbeck, Mark A. Socinski. (2008) The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 145-151
CrossRef256
Erin Powell, Laura QM Chow. (2008) BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer. Expert Review of Respiratory Medicine 2:1, 37-45
CrossRef257
Boone Goodgame, Avinash Viswanathan, C Ryan Miller, Feng Gao, Bryan Meyers, Richard J. Battafarano, Alexander Patterson, Joel Cooper, Tracey J. Guthrie, Jeffrey Bradley, Giancarlo Pillot, Ramaswamy Govindan. (2008) A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 31:1, 22-28
CrossRef258
Tony S. K. Mok, John Crowley. (2008) Big Question, Small Answer. Journal of Thoracic Oncology 3:2, 105-106
CrossRef259
Boone Goodgame, Giancarlo A. Pillot, Zhiyun Yang, Jabi Shriki, Bryan F. Meyers, Jennifer Zoole, Feng Gao, Farrokh Dehdashti, Alexander Patterson, Barry A. Siegel, Ramaswamy Govindan. (2008) Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 130-134
CrossRef260
Riichiroh Maruyama, Ichiro Yoshino, Shoji Tokunaga, Morio Ohta, Masato Kato, Hiroyuki Yoshimine, Koji Yamazaki, Yoichi Nakanishi, Yukito Ichinose. (2008) Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501. General Thoracic and Cardiovascular Surgery 56:2, 68-73
CrossRef261
Kathryn L. Howe, Natasha B. Leighl. (2008) Factors Contributing to Adjuvant Therapy Decisions. Journal of Thoracic Oncology 3:2, 195-196
CrossRef262
Jue Wang, Yong Fang Kuo, Jean Freeman, Avi B. Markowitz, James S. Goodwin. (2008) Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 112:2, 382-390
CrossRef263
Haruhisa Matsuguma, Rie Nakahara, Seiji Igarashi, Yoshinori Ishikawa, Haruko Suzuki, Naoto Miyazawa, Satoshi Honjo, Kohei Yokoi. (2008) Pathologic stage I non–small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis. The Journal of Thoracic and Cardiovascular Surgery 135:1, 44-49
CrossRef264
Jin Gu Lee, Chang Young Lee, In Kyu Park, Dae Joon Kim, Sang Ho Cho, Kil Dong Kim, Kyung Young Chung. (2008) The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer. Journal of Korean Medical Science 23:4, 604
CrossRef265
Corey J Langer. (2008) Resectable Non-Small Cell Lung Cancer in the Elderly. Drugs & Aging 25:3, 209-218
CrossRef266
David E. Midthun, James R. Jett. 2008. Lung Tumors. , 605-631.
CrossRef267
Anna-Liisa Kautio, Maija Haanpää, Tiina Saarto, Eija Kalso. (2008) Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms. Journal of Pain and Symptom Management 35:1, 31-39
CrossRef268
Wilfried Eberhardt, Rainer Fietkau, Martin Reck. (2008) Therapie des älteren Patienten. Onkologie 31:3, 15-22
CrossRef269
Christopher G. Azzoli, Bernard J. Park, William Pao, Maureen Zakowski, Mark G. Kris. (2008) Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:1, 84-93
CrossRef270
Po-Kuei Hsu, Hsu-Chih Huang, Chih-Cheng Hsieh, Han-Shui Hsu, Yu-Chung Wu, Min-Hsiung Huang, Wen-Hu Hsu. (2007) Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 84:6, 1825-1829
CrossRef271
Rebecca M. Woodward, Martin L. Brown, Susan T. Stewart, Kathleen A. Cronin, David M. Cutler. (2007) The value of medical interventions for lung cancer in the elderly. Cancer 110:11, 2511-2518
CrossRef272
Marcello Tiseo, Andrea Ardizzoni. (2007) Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. Oncology Reviews 1:3, 162-169
CrossRef273
Lynn T. Tanoue, Scott Gettinger. (2007) Treatment of Lung Cancer in Older Patients. Clinics in Chest Medicine 28:4, 735-749
CrossRef274
Alessandro Borri, Francesco Leo, Giulia Veronesi, Piergiorgio Solli, Domenico Galetta, Roberto Gasparri, Francesco Petrella, Paolo Scanagatta, Davide Radice, Lorenzo Spaggiari. (2007) Extended pneumonectomy for non–small cell lung cancer: Morbidity, mortality, and long-term results. The Journal of Thoracic and Cardiovascular Surgery 134:5, 1266-1272
CrossRef275
Mark N. Kirstein, Katie M. Wieman, Brent W. Williams, James E. Fisher, Paul H. Marker, Chap T. Le, Douglas Yee, Robert A. Kratzke. (2007) Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. Lung Cancer 58:2, 196-204
CrossRef276
Valerie W. Rusch. (2007) Adjuvant Therapy in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 84:5, 1793-1794
CrossRef277
Adrian Gillissen. (2007) American Thoracic Society Annual International Congress. Expert Opinion on Pharmacotherapy 8:16, 2885-2891
CrossRef278
Fabrizio Bianchi, Paolo Nuciforo, Manuela Vecchi, Loris Bernard, Laura Tizzoni, Antonio Marchetti, Fiamma Buttitta, Lara Felicioni, Francesco Nicassio, Pier Paolo Di Fiore. (2007) Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. Journal of Clinical Investigation 117:11, 3436-3444
CrossRef279
Ariel Anguiano, Anil Potti. (2007) Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer. Expert Review of Molecular Diagnostics 7:6, 837-844
CrossRef280
Sabine Danzinger, Martin Filipits. (2007) Biomarker – der Weg zur individualisierten Chemotherapie beim nicht-kleinzelligen Bronchialkarzinom. Wiener Medizinische Wochenschrift 157:21-22, 554-561
CrossRef281
Fumihiro Tanaka. (2007) UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surgery Today 37:11, 923-943
CrossRef282
Giuseppe Giaccone, Egbert Smit, Suresh Senan, Rick Paul. 2007. Multidisciplinary Team Management of Lung Cancer. .
CrossRef283
Yoshio Tomizawa, Shin-ichi Ishihara, Hironobu Iijima, Hisao Imai, Koji Sato, Masakiyo Yatomi, Yasuki Iwasaki, Hidenori Yamada, Go Kobayashi, Emi Ishida, Teruki Inoue, Haruka Aoki, Satoru Watanabe, Osamu Kawashima, Masatomo Mori, Ryusei Saito. (2007) A Phase I Dose Escalation Study of Biweekly Gemcitabine and Carboplatin in Completely Resected Stage IB-IIIA Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 30:5, 498-502
CrossRef284
Michael F. Reed, William A. Zagorski, Erik S. Knudsen. (2007) RB Activity Alters Checkpoint Response and Chemosensitivity in Lung Cancer Lines. Journal of Surgical Research 142:2, 364-372
CrossRef285
S.-H. Ignatius Ou, Jason A. Zell, Argyrios Ziogas, Hoda Anton-Culver. (2007) Prognostic factors for survival of stage I nonsmall cell lung cancer patients. Cancer 110:7, 1532-1541
CrossRef286
V. Westeel. (2007) La chimiothérapie périopératoire des carcinomes bronchiques non à petites cellules en pratique. Revue des Maladies Respiratoires 24:8, 69-72
CrossRef287
M. Wislez, M. Antoine, A. Lavolé, V. Gounant, B. Milleron, J. Cadranel. (2007) Prédiction de la réponse à la chimiothérapie dans les CBNPC : applications pratiques. Revue des Maladies Respiratoires 24:8, 206-210
CrossRef288
Elisabetta Campagnoli, Isabella Garassino, Armando Santoro, Fabio De Vincenzo, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Fabio Romano Lutman, Marco Alloisio, Hector Josè Soto Parra, Raffaele Cavina. (2007) Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Investigational New Drugs 25:6, 559-564
CrossRef289
Naruyuki Kobayashi, Shinichi Toyooka, Junichi Soh, Kouichi Ichimura, Hiroyuki Yanai, Hiroshi Suehisa, Shuji Ichihara, Masaomi Yamane, Motoi Aoe, Yoshifumi Sano, Hiroshi Date. (2007) Risk Factors for Recurrence and Unfavorable Prognosis in Patients with Stage I Non-small Cell Lung Cancer and a Tumor Diameter of 20 mm or Less. Journal of Thoracic Oncology 2:9, 808-812
CrossRef290
Ryuta Fukai, Yukinori Sakao, Motoki Sakuraba, Shiaki Oh, Kazu Shiomi, Satoshi Sonobe, Yuichi Saitoh, Hideaki Miyamoto. (2007) The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung. European Journal of Cardio-Thoracic Surgery 32:3, 440-444
CrossRef291
Linda W. Martin, Arlene M. Correa, Nelson G. Ordonez, Jack A. Roth, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, David C. Rice. (2007) Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis. The Annals of Thoracic Surgery 84:3, 973-980
CrossRef292
Thomas E. Stinchcombe, Frank C. Detterbeck, Li Lin, M Patricia Rivera, Mark A. Socinski. (2007) Beliefs among Physicians in the Diagnostic and Therapeutic Approach to Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:9, 819-826
CrossRef293
F. Honecker, I. Thoem, D. Branscheid, T.G. Wendt. (2007) Bronchialkarzinom. Der Onkologe 13:9, 823-830
CrossRef294
Jan P. van Meerbeeck, Rebecca De Pauw. (2007) Neoadjuvant chemotherapy in early stage non-small cell lung cancer. European Journal of Cancer Supplements 5:5, 377-379
CrossRef295
Si-yu Wang, Wei Ou, Yong-bin Lin, Ying Liang, Xiong Ye, Bin-bin Zhang, Hua Yang. (2007) A prospective randomized study of adjuvant chemotherapy in completely resected stage III-N2 non small cell lung cancer. Chinese Journal of Cancer Research 19:3, 189-194
CrossRef296
Peter Goldstraw. (2007) The 7th Edition of the TNM Classification for Lung Cancer: Proposals from the IASLC Staging Project. European Journal of Cancer Supplements 5:5, 15-22
CrossRef297
Gerold Bepler. (2007) Phase II Pharmacogenomics-Based Adjuvant Therapy Trial in Patients with Non–Small-Cell Lung Cancer:Southwest Oncology Group Trial 0720. Clinical Lung Cancer 8:8, 509-511
CrossRef298
Ichiro Yoshino, Yoshihiko Maehara. (2007) Impact of Smoking Status on the Biological Behavior of Lung Cancer. Surgery Today 37:9, 725-734
CrossRef299
Tomoyoshi Takenaka, Ichiro Yoshino, Hidenori Kouso, Taro Ohba, Tomofumi Yohena, Atsushi Osoegawa, Fumihiro Shoji, Yoshihiko Maehara. (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. International Journal of Cancer 121:4, 895-900
CrossRef300
Brian E. Lally, Frank C. Detterbeck, Ann M. Geiger, Charles R. Thomas, Mitchell Machtay, Antonius A. Miller, Lynn D. Wilson, Timothy E. Oaks, W. Jeffrey Petty, Mike E. Robbins, A. William Blackstock. (2007) The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy. Cancer 110:4, 911-917
CrossRef301
M. Seike, N. Yanaihara, E. D. Bowman, K. A. Zanetti, A. Budhu, K. Kumamoto, L. E. Mechanic, S. Matsumoto, J. Yokota, T. Shibata, H. Sugimura, A. Gemma, S. Kudoh, X. W. Wang, C. C. Harris. (2007) Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier. JNCI Journal of the National Cancer Institute 99:16, 1257-1269
CrossRef302
Eugene H. Blackstone, Thomas W. Rice. (2007) From Trees to Wood and Back: Perspective on Clinical Data Analysis in Thoracic Surgery. Thoracic Surgery Clinics 17:3, 309-327
CrossRef303
Timothy R. Wassenaar, Jens C. Eickhoff, Daniel R. Jarzemsky, Stevens S. Smith, Marilyn L. Larson, Joan H. Schiller. (2007) Differences in Primary Care Clinicians?? Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer. Journal of Thoracic Oncology 2:8, 722-728
CrossRef304
Thierry Le Chevalier. (2007) Adjuvant treatment for resectable lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S241-S242
CrossRef305
Giovanni Selvaggi, Giorgio Vittorio Scagliotti. (2007) Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine 1:1, 99-110
CrossRef306
Peter Goldstraw, John Crowley, Kari Chansky, Dorothy J. Giroux, Patti A. Groome, Ramon Rami-Porta, Pieter E. Postmus, Valerie Rusch, Leslie Sobin. (2007) The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology 2:8, 706-714
CrossRef307
Giorgio V. Scagliotti, Giovanni Selvaggi. (2007) Adjuvant therapies: what we have learned in the last 5 years. Journal of Thoracic Oncology 2:Supplement 4, S299-S230
CrossRef308
William K. Evans. (2007) The cost of care for patients with lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S209-S210
CrossRef309
Akira Iyoda, Kenzo Hiroshima, Yukio Nakatani, Takehiko Fujisawa. (2007) Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma
A part of this report was presented by Iyoda A et al. Pulmonary large cell neuroendocrine carcinoma. JJLC 2006;46:315–20 [in Japanese with English abstract].. The Annals of Thoracic Surgery 84:2, 702-707
CrossRef310
Ming S. Tsao. (2007) Genomic signatures of prognosis in early stage non-small cell lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S168-S169
CrossRef311
Martin Sebastian, Bernward Passlick, Hilke Friccius-Quecke, Michael Jäger, Horst Lindhofer, Frank Kanniess, Rainer Wiewrodt, Eckhard Thiel, Roland Buhl, Alexander Schmittel. (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunology, Immunotherapy 56:10, 1637-1644
CrossRef312
Masafumi Kawamura, Keisuke Eguchi, Yotaro Izumi, Yasushi Yamato, Teruaki Koike, Hirozo Sakaguchi, Enjo Hada, Koichi Kobayashi. (2007) Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA–IIIA non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 60:4, 495-501
CrossRef313
Christopher G. Azzoli, Lee M. Krug, Vincent A. Miller, Naiyer A. Rizvi, Mark G. Kris, Megan Dunne, Amy Farmer, Barbara Pizzo, Leslie Tyson, Teresa Seeger, Barbara Coleman, Erin Moore, Lauren Lastinger, Ennapadam Venkatraman, Charles M. Rudin. (2007) A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:7, 638-644
CrossRef314
David R. Gandara, Heather Wakelee, Royce Calhoun, David Jablons. (2007) Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America. Journal of Thoracic Oncology 2:Supplement 3, S125-S127
CrossRef315
Robert J. Cerfolio, Ayesha S. Bryant. (2007) Predictors of Survival and Disease-Free Survival in Patients With Resected N1 Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 84:1, 182-190
CrossRef316
Amy E. Gallo, Jessica S. Donington. (2007) The role of surgery in the treatment of stage III non—small-cell lung cancer. Current Oncology Reports 9:4, 247-254
CrossRef317
Laurent Brouchet, Eric Bauvin, Bertrand Marcheix, Laurence Bigay-Game, Claire Renaud, Jean Berjaud, Pierre Emmanuel Falcoze, Nicolas Venissac, Dan Raz, David Jablons, Julien Mazières, Marcel Dahan. (2007) Impact of Induction Treatment on Postoperative Complications in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:7, 626-631
CrossRef318
Ken André Olaussen, Giannis Mountzios, Jean-Charles Soria. (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Current Opinion in Pulmonary Medicine 13:4, 284-289
CrossRef319
Cesare Gridelli, Matti S. Aapro, Sandro Barni, Giordano Domenico Beretta, Giuseppe Colucci, Bruno Daniele, Lucia Del Mastro, Massimo Di Maio, Luigi De Petris, Francesco Perrone, Nick Thatcher, Filippo De Marinis. (2007) Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel. Critical Reviews in Oncology/Hematology 63:1, 53-64
CrossRef320
Katherine M. W. Pisters, Gail Darling. (2007) The IASLC Lung Cancer Staging Project: ???The Nodal Zone???. Journal of Thoracic Oncology 2:7, 583-584
CrossRef321
K. Yanagisawa, S. Tomida, Y. Shimada, Y. Yatabe, T. Mitsudomi, T. Takahashi. (2007) A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 99:11, 858-867
CrossRef322
C. G. Azzoli, M. G. Kris, D. G. Pfister. (2007) Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed. JNCI Journal of the National Cancer Institute 99:11, 828-829
CrossRef323
Frances A Shepherd, Rafael Rosell. (2007) Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Suppl 2, S68-S76
CrossRef324
F. Barlési, J.-M. Bréchot, G. Zalcman. (2007) Dans les cancers bronchiques non à petites cellules opérés, le taux d’expression intratumorale d’ERCC1 influence l’efficacité d’une chimiothérapie postopératoire basée sur le cisplatine. Revue des Maladies Respiratoires 24, 56-57
CrossRef325
Takashi Uno, Minako Sumi, Ayaka Kihara, Hodaka Numasaki, Hiroyuki Kawakami, Hiroshi Ikeda, Michihide Mitsumori, Teruki Teshima. (2007) Postoperative radiotherapy for non-small-cell lung cancer: Results of the 1999–2001 patterns of care study nationwide process survey in Japan. Lung Cancer 56:3, 357-362
CrossRef326
Penelope A Bradbury, Frances A Shepherd. (2007) Chemotherapy and surgery for operable NSCLC. The Lancet 369:9577, 1903-1904
CrossRef327
F. Barlési, J.-M. Bréchot, G. Zalcman. (2007) La chimiothérapie adjuvante est bien un standard de traitement pour les patients opérés d’un cancer bronchique non à petites cellules de stade II ou III. Revue des Maladies Respiratoires 24, 58
CrossRef328
Richard F. Riedel, Carolyn Andrews, Jennifer Garst, Frank Dunphy, James E. Herndon, Susan Blackwell, Sally Barbour, Jeffrey Crawford. (2007) A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:6, 520-525
CrossRef329
Janis M. Taube, Frederic B. Askin, Malcolm V. Brock, William Westra. (2007) Impact of Elastic Staining on the Staging of Peripheral Lung Cancers. The American Journal of Surgical Pathology 31:6, 953-956
CrossRef330
Tomoshi Tsuchiya, Shinji Akamine, Masashi Muraoka, Ryotaro Kamohara, Koichi Tsuji, Shogo Urabe, Sumihisa Honda, Naoya Yamasaki. (2007) Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 56:3, 341-348
CrossRef331
T E Stinchcombe, M A Socinski. (2007) Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 26:25, 3691-3698
CrossRef332
Joe Y. Chang, Jack A. Roth. (2007) Stereotactic Body Radiation Therapy for Stage I Non–Small Cell Lung Cancer. Thoracic Surgery Clinics 17:2, 251-259
CrossRef333
Eric Vallières. (2007) Role of Adjuvant Systemic Therapy for Stage I NSCLC. Thoracic Surgery Clinics 17:2, 279-285
CrossRef334
David H. Harpole. (2007) Prognostic Modeling in Early Stage Lung Cancer: An Evolving Process from Histopathology to Genomics. Thoracic Surgery Clinics 17:2, 167-173
CrossRef335
Bernard Milleron, Isabelle Debrix, Valerie Gounand, Marie Wislez. (2007) Impact of Randomized Clinical Trials on Clinical Practice Regarding Treatment of Lung Cancer. Journal of Thoracic Oncology 2:5, 456
CrossRef336
Michael T. Milano, Yuhchyau Chen. 2007. Advances in Chemoradiation Treatment of Locoregionally Advanced Non–Small Cell Lung Cancer. , 175-206.
CrossRef337
Emilio Bria, Federica Cuppone, Fabiana Letizia Cecere, Michele Milella, Cecilia Nisticò, Francesco Cognetti, Edmondo Terzoli. (2007) Adjuvant Chemotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S7-S11
CrossRef338
Julie R. BRAHMER, David S. ETTINGER. (2007) Non-small cell lung cancer: Adjuvant and neo-adjuvant chemotherapy. Respirology 12:3, 320-325
CrossRef339
Leora Horn, Alan Sandler. (2007) Lung Cancer Adjuvant Therapy. The Cancer Journal 13:3, 210-216
CrossRef340
Ara Ketchedjian, Thomas A. DiPetrillo, Benedict Daly, Hiran C. Fernando. (2007) Role of Adjuvant Radiation (External Beam/Brachytherapy) for Stage I NSCLC. Thoracic Surgery Clinics 17:2, 273-278
CrossRef341
Lucyna Kepka, Vera Danilova, Tatul Saghatelyan, Andras Bajcsay, Olga Utehina, Suzana Stojanovic, Deniz Yalman, Ayse Demiral, Olga Bondaruk, Maire Kuddu, Branislav Jeremic. (2007) Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: Results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 56:2, 235-245
CrossRef342
Leora Horn, Alan B. Sandler, Joe B. Putnam, David H. Johnson. (2007) The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:5, 377-383
CrossRef343
Norihisa Shigemura, Anthony P.C. Yim. (2007) Variation in the Approach to VATS Lobectomy: Effect on the Evaluation of Surgical Morbidity Following VATS Lobectomy for the Treatment of Stage I Non–Small Cell Lung Cancer. Thoracic Surgery Clinics 17:2, 233-239
CrossRef344
Rebecca P. Petersen, DuyKhanh Pham, William R. Burfeind, Steven I. Hanish, Eric M. Toloza, David H. Harpole, Thomas A. D’Amico. (2007) Thoracoscopic Lobectomy Facilitates the Delivery of Chemotherapy after Resection for Lung Cancer. The Annals of Thoracic Surgery 83:4, 1245-1250
CrossRef345
Suresh Ramalingam, Chandra P Belani. (2007) Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncology 3:2, 131-139
CrossRef346
Daniel B. Costa, Sigui Li, Olivier Kocher, Richard H. Feins, Steven M. Keller, Joan H. Schiller, David H. Johnson, Daniel G. Tenen, Balazs Halmos. (2007) Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590. Lung Cancer 56:1, 97-103
CrossRef347
Steven J. Feigenberg, Alexandra L. Hanlon, Corey Langer, Melvyn Goldberg, Nicos Nicolaou, Michael Millenson, Lawrence R. Coia, Rachelle Lanciano, Benjamin Movsas. (2007) A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:4, 287-292
CrossRef348
Adrian Gillissen. (2007) Meeting highlights of the European Respiratory Society annual congress. Expert Opinion on Pharmacotherapy 8:5, 711-717
CrossRef349
J. P. van Meerbeeck, G. W. P. M. Kramer, P. E. Y. Van Schil, C. Legrand, E. F. Smit, F. Schramel, V. C. Tjan-Heijnen, B. Biesma, C. Debruyne, N. van Zandwijk, T. A. W. Splinter, G. Giaccone. (2007) Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 99:6, 442-450
CrossRef350
Rex De L. Stanbridge, Jimmy K. F. Hon, Elizabeth Bateman, Sian Roberts. (2007) Minimally Invasive Anterior Thoracotomy for Routine Lung Cancer Resection. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 2:2, 76-83
CrossRef351
Tania Cortas, Rosana Eisenberg, Pingfu Fu, Jeffrey Kern, Lauren Patrick, Afshin Dowlati. (2007) Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 55:3, 349-355
CrossRef352
Benjamin Enoch Lee, Derek von Haag, Teri Lown, Derick Lau, Royce Calhoun, David Follette. (2007) Advances in positron emission tomography technology have increased the need for surgical staging in non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 133:3, 746-752
CrossRef353
I. Gauthier, K. Ding, T. Winton, F.A. Shepherd, R. Livingston, D.H. Johnson, J.R. Rigas, M. Whitehead, B. Graham, L. Seymour. (2007) Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience. Lung Cancer 55:3, 357-363
CrossRef354
Rebecca De Pauw, Jan P van Meerbeeck. (2007) Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer. Current Opinion in Oncology 19:2, 92-97
CrossRef355
Suresh Ramalingam, Chandra P Belani. (2007) Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets 11:2, 245-257
CrossRef356
Herbst, Roy S., Lippman, Scott M., . (2007) Molecular Signatures of Lung Cancer — Toward Personalized Therapy. New England Journal of Medicine 356:1, 76-78
Full Text357
Shunzo Hatooka, Shouichi Mori, Takayuki Fukui, Masayuki Shinoda, Noriaki Sakakura, Katsuhiro Okuda, Tatsuya Katayama, Futoshi Ishiguro, Tetsuya Mitsudomi. (2007) Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer. Haigan 47:4, 327-332
CrossRef358
N.H. Hanna. (2007) Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Longterm survival in a randomized study. Yearbook of Medicine 2007, 149-151
CrossRef359
Lorenzo Spaggiari, Francesco Leo, Giulia Veronesi, Piergiorgio Solli, Domenico Galetta, Brunilda Tatani, Francesco Petrella, Davide Radice. (2007) Superior Vena Cava Resection for Lung and Mediastinal Malignancies: A Single-Center Experience With 70 Cases. The Annals of Thoracic Surgery 83:1, 223-230
CrossRef360
L.T. Tanoue. (2007) An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Yearbook of Pulmonary Disease 2007, 150-152
CrossRef361
Tatsuya Yoshimasu, Shoji Oura, Takeshi Tamaki, Fuminori Ota, Rie Nakamura, Yukio Shimizu, Yoshimitsu Hirai, Koma Naito, Megumi Kiyoi, Mitsumasa Kawago, Yoshitaka Okamura. (2007) Adjuvant chemotherapy with paclitaxel for non-small cell lung cancer. The Journal of the Japanese Associtation for Chest Surgery 21:7, 882-885
CrossRef362
Thomas E Stinchcombe, Mark A Socinski. (2007) The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer. Drugs 67:3, 321-332
CrossRef363
Lioe-Fee de Geus-Oei, J. Han J.M. van Krieken, Riena P. Aliredjo, Paul F.M. Krabbe, Cathelijne Frielink, Ad F.T. Verhagen, Otto C. Boerman, Wim J.G. Oyen. (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55:1, 79-87
CrossRef364
N.H. Hanna. (2007) Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Longterm survival in a randomized study. Yearbook of Oncology 2007, 181-183
CrossRef365
Ulrich Gatzemeier, Frank Griesinger, Rudolf M. Huber, Michael Thomas. (2007) Tumortherapie im Spannungsfeld von Pharmakoökonomie und Innovation*. Onkologie 30:1, 11-16
CrossRef366
Farrah Kassam, Frances A. Shepherd, Michael Johnston, Antonio Visbal, Ronald Feld, Gail Darling, Shaf Keshavjee, Andrew Pierre, Thomas Waddell, Natasha B. Leighl. (2007) Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:1, 39-43
CrossRef367
K. A. Cheong, K. Chrystal, P. G. Harper. (2007) Adjuvant chemotherapy in non-small cell lung cancer. International Journal of Clinical Practice 61:1, 143-146
CrossRef368
Paolo Macchiarini, Matthias Altmayer, Tetsuhiko Go, Thorsten Walles, Karl Schulze, Ingeborg Wildfang, Axel Haverich, Michael Hardin. (2006) Technical Innovations of Carinal Resection for Nonsmall-Cell Lung Cancer. The Annals of Thoracic Surgery 82:6, 1989-1997
CrossRef369
Takashi Ohtsuka, Hiroaki Nomori, Ken-ichi Watanabe, Masahiro Kaji, Tsuguo Naruke, Keiichi Suemasu, Kimiichi Uno. (2006) Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 107:10, 2468-2473
CrossRef370
Akira Iyoda, Kenzo Hiroshima, Yasumitsu Moriya, Yuichi Takiguchi, Yasuo Sekine, Kiyoshi Shibuya, Toshihiko Iizasa, Hideki Kimura, Yukio Nakatani, Takehiko Fujisawa. (2006) Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma. The Annals of Thoracic Surgery 82:5, 1802-1807
CrossRef371
Aarati Ranganathan, Alex Adjei, Primo Lara. (2006) 2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25–26, 2006. Clinical Lung Cancer 8:3, 170-178
CrossRef372
Chumy Nwogu, Gabor Fischer, DongFeng Tan, Michal Glinianski, Dominick Lamonica, Todd Demmy. (2006) Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 82:5, 1815-1820
CrossRef373
J. de Castro Carpeño, C. Belda-Iniesta, J. Feliu Batlle, M. González Barón. (2006) Cáncer de pulmón (II). Tratamiento médico. Medicine - Programa de Formación Médica Continuada Acreditado 9:66, 4265-4269
CrossRef374
Jacek Jassem. (2006) Postoperative chemotherapy in non-small cell lung cancer: still more questions than answers. Future Oncology 2:5, 569-571
CrossRef375
M Nazir Ibrahim, Zarina Abdullah, Michael J Martin. (2006) Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. Expert Review of Anticancer Therapy 6:10, 1397-1410
CrossRef376
Quynh-Thu Le, Billy W. Loo, Anthony Ho, Christian Cotrutz, Albert C. Koong, Heather Wakelee, Stephen T. Kee, Dana Constantinescu, Richard I. Whyte, Jessica Donington. (2006) Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. Journal of Thoracic Oncology 1:8, 802-809
CrossRef377
Olaussen, Ken A., Dunant, Ariane, Fouret, Pierre, Brambilla, Elisabeth, André, Fabrice, Haddad, Vincent, Taranchon, Estelle, Filipits, Martin, Pirker, Robert, Popper, Helmut H., Stahel, Rolf, Sabatier, Laure, Pignon, Jean-Pierre, Tursz, Thomas, Le Chevalier, Thierry, Soria, Jean-Charles, . (2006) DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. New England Journal of Medicine 355:10, 983-991
Full Text378
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, Jose Luis Gonzáles-Larriba, Tomasz Grodzki, Jose Rodrigues Pereira, Alain Le Groumellec, Vito Lorusso, Claude Clary, Antonio J Torres, Jabrail Dahabreh, Pierre-Jean Souquet, Julio Astudillo, Pierre Fournel, Angel Artal-Cortes, Jacek Jassem, Leona Koubkova, Patricia His, Marcello Riggi, Patrick Hurteloup. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The Lancet Oncology 7:9, 719-727
CrossRef379
Pierre-Jean Souquet, Laurence Geriniere. (2006) Docetaxel in non-small cell lung cancer. Therapy 3:5, 579-590
CrossRef380
Christopher G Azzoli. (2006) Adjuvant chemotherapy for resected non-small-cell lung cancer—ANITA takes the stage. The Lancet Oncology 7:9, 701-703
CrossRef381
Norihisa Shigemura, Akinori Akashi, Soichiro Funaki, Tomoyuki Nakagiri, Masayoshi Inoue, Noriyoshi Sawabata, Hiroyuki Shiono, Masato Minami, Yukiyasu Takeuchi, Meinoshin Okumura, Yoshiki Sawa. (2006) Long-term outcomes after a variety of video-assisted thoracoscopic lobectomy approaches for clinical stage IA lung cancer: A multi-institutional study. The Journal of Thoracic and Cardiovascular Surgery 132:3, 507-512
CrossRef382
Mario Roselli, Sabrina Mariotti, Patrizia Ferroni, Anastasia Laudisi, Davide Mineo, Eugenio Pompeo, Vincenzo Ambrogi, Tommaso C. Mineo. (2006) Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. International Journal of Cancer 119:4, 955-960
CrossRef383
Potti, Anil, Mukherjee, Sayan, Petersen, Rebecca, Dressman, Holly K., Bild, Andrea, Koontz, Jason, Kratzke, Robert, Watson, Mark A., Kelley, Michael, Ginsburg, Geoffrey S., West, Mike, Harpole, David H. Jr., Nevins, Joseph R., . (2006) A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer. New England Journal of Medicine 355:6, 570-580
Full Text384
M. Thomas, H. Dienemann, D. Branscheid, N. Dickgreber, M. Steins, M. Kreuter, N. Reinmuth, F. Griesinger, N. Niederle. (2006) Neoadjuvante/adjuvanteTherapie in den frühen Stadien des nichtkleinzelligen Lungenkarzinoms. Der Onkologe 12:8, 737-745
CrossRef385
Rebecca P. Petersen, DuyKhanh Pham, Eric M. Toloza, William R. Burfeind, David H. Harpole, Steven I. Hanish, Thomas A. D’Amico. (2006) Thoracoscopic Lobectomy: A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 82:1, 214-219
CrossRef386
Aarati Ranganathan, David R. Gandara. (2006) 2006 Highlights From: 42nd Annual Meeting of the American Society of Clinical Oncology Atlanta, GA, June 2006. Clinical Lung Cancer 8:1, 13-17
CrossRef387
Giulia Veronesi, Uliano Morandi, Marco Alloisio, Alberto Terzi, Giuseppe Cardillo, Pierluigi Filosso, Federico Rea, Francesco Facciolo, Giuseppe Pelosi, Sara Gandini, Francesco Calabrò, Christian Casali, Giuseppe Marulli, Lorenzo Spaggiari. (2006) Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases. Lung Cancer 53:1, 111-115
CrossRef388
Anil Potti, Apar Kishor Ganti. (2006) Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. Expert Opinion on Biological Therapy 6:7, 709-716
CrossRef389
Joe Y. Chang, Jennifer Moughan, David W. Johnstone, Ritsuko Komaki, Melvyn Goldberg, Corey J. Langer, Beth M. Beadle, Jean Owen, Benjamin Movsas. (2006) Surgical Patterns of Care in Operable Lung Carcinoma Treated with Radiation. Journal of Thoracic Oncology 1:6, 526-531
CrossRef390
G. Fernandes, M. Sucena, E. Lombardia, A. Machado, V. Hespanhol, H. Queiroga, Doutor J. Agostinho Marques. (2006) Cancro do pulmão de não pequenas células – Comparação entre o estadiamento clínico e o patológico. Revista Portuguesa de Pneumologia (English Edition) 12:4, 337-357
CrossRef391
Francesco Grossi, Marcello Tiseo. (2006) Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology 58:3, 221-230
CrossRef392
R. M. Huber. (2006) Lungenkarzinom. Der Internist 47:6, 611-622
CrossRef393
Jeffrey A. Jones, Elenir B. C. Avritscher, Catherine D. Cooksley, Marisol Michelet, B. Nebiyou Bekele, Linda S. Elting. (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive Care in Cancer 14:6, 505-515
CrossRef394
John F. Bruzzi, Mylene Truong, Ralph Zinner, Jeremy J. Erasmus, Bradley Sabloff, Reginald Munden. (2006) Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy. Journal of Thoracic Oncology 1:5, 425-429
CrossRef395
Thomas A. D’Amico, Kelli R. Brooks, Mary-Beth Moore Joshi, Debbi Conlon, James Herndon, Rebecca P. Petersen, David H. Harpole. (2006) Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection. The Annals of Thoracic Surgery 81:6, 1982-1987
CrossRef396
Francesco Leo, Alessandro Borri, Francesco Petrella, Roberto Gasparri, Domenico Galetta, Giulia Veronesi, Lorenzo Spaggiari. (2006) Preoperative Chemotherapy and Postoperative Complications: A Closer Look. The Annals of Thoracic Surgery 81:6, 2335
CrossRef397
Steven C. Rose, Patricia A. Thistlethwaite, Patrick E. Sewell, Ralph B. Vance. (2006) Lung Cancer and Radiofrequency Ablation. Journal of Vascular and Interventional Radiology 17:6, 927-951
CrossRef398
C-Q Zhu, J-C Cutz, N Liu, D Lau, F A Shepherd, J A Squire, M-S Tsao. (2006) Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. British Journal of Cancer 94:10, 1452-1459
CrossRef399
C Mascaux. (2006) Reply: K-Ras: a prognostic factor for survival in non-small cell lung cancer. British Journal of Cancer 94:10, 1549-1549
CrossRef400
G Ferretti, A Felici, F Cognetti. (2006) Ras oncogene mutations and survival in patients with lung cancer. British Journal of Cancer 94:10, 1548-1548
CrossRef401
Naveed Alam, Gail Darling, William K. Evans, Jean A. Mackay, Frances A. Shepherd. (2006) Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review. Critical Reviews in Oncology/Hematology 58:2, 146-155
CrossRef402
M.-O. Grimm, F. H. Hartmann, R. Ackermann. (2006) Zukunft der Chemotherapie. Der Urologe 45:5, 567-571
CrossRef403
Sarita Dubey, Jill M Siegfried, Anne M Traynor. (2006) Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. The Lancet Oncology 7:5, 416-424
CrossRef404
Peter M. Ravdin, Gregory Davis. (2006) Prognosis of patients with resected non-small cell lung cancer: Impact of clinical and pathologic variables. Lung Cancer 52:2, 207-212
CrossRef405
Feng-Ming (Spring) Kong, Lujun Zhao, James A. Hayman. (2006) The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America 20:2, 363-400
CrossRef406
Hans-Stefan Hofmann. (2006) The wind of change in the therapy of lung cancer. Expert Review of Anticancer Therapy 6:4, 469-472
CrossRef407
Katsuyuki Hotta, Keitaro Matsuo, Katsuyuki Kiura, Hiroshi Ueoka, Mitsune Tanimoto. (2006) Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Current Opinion in Oncology 18:2, 144-150
CrossRef408
Rafael Rosell, Mauricio Cuello, Fabiana Cecere, Mariacarmela Santarpia, Noemi Reguart, Enriqueta Felip, Miquel Taron. (2006) Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Current Opinion in Oncology 18:2, 135-143
CrossRef409
Edward J. Crane, George Simon. (2006) Adjuvant chemotherapy for non-small cell lung cancer. Current Treatment Options in Oncology 7:1, 51-58
CrossRef410
A. End. (2006) Diagnosis and treatment of lung cancer – Non-small cell lung cancer, small cell lung cancer and carcinoids. European Surgery 38:1, 45-53
CrossRef411
Antonio Saha, Robin Rudd. (2006) Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?. Expert Review of Anticancer Therapy 6:2, 165-173
CrossRef412
Mark A. Socinski, Thomas E. Stinchcombe, D. Neil Hayes, David E. Morris. (2006) The Emergence of a Unique Population in Non–Small Cell Lung Cancer: Systemic or Loco-Regional Relapse Following Postoperative Adjuvant Platinum-Based Chemotherapy. Seminars in Oncology 33, 32-38
CrossRef413
Christopher M. Booth, Frances A. Shepherd. (2006) Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:2, 180-187
CrossRef414
Rafael Rosell, Fabiana Cecere, Francesco Cognetti, Mauricio Cuello, Jose Miguel Sanchez, Miquel Taron, Noemi Reguart, David Jablons. (2006) Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer. Seminars in Oncology 33, 45-51
CrossRef415
Paolo Andrea Zucali, Hector Jose Soto Parra, Raffaele Cavina, Elisabetta Campagnoli, Fiorenza Latteri, Fabio De Vincenzo, Giovanni Luca Ceresoli, Maria Fazio, Marco Alloisio, Armando Santoro. (2006) Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer. Oncology 71:3-4, 229-236
CrossRef416
Akira Iyoda, Kenzo Hiroshima, Yukio Nakatani, Takehiko Fujisawa. (2006) Pulmonary Large Cell Neuroendocrine Carcinoma. Haigan 46:4, 315-320
CrossRef417
Michael Fanucchi, Fadlo R Khuri. (2006) Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine 5:3, 181-191
CrossRef418
Marc de Perrot, Elie Fadel, Olaf Mercier, Sacha Mussot, Alain Chapelier, Philippe Dartevelle. (2006) Long-term results after carinal resection for carcinoma: Does the benefit warrant the risk?. The Journal of Thoracic and Cardiovascular Surgery 131:1, 81-89
CrossRef419
Daniel C. Betticher. (2005) Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. Lung Cancer 50, S9-S16
CrossRef420
Marissa DANIELS, Genni M NEWNHAM, Gavin M WRIGHT. (2005) From evidence to practice: Audit of adjuvant chemotherapy after complete resection of non-small cell lung cancer in an Australian lung cancer center. Asia-Pacific Journal of Clinical Oncology 1:4, 138-144
CrossRef421
Gavin Wright. (2005) Clinical scenarios in thoracic surgery.. ANZ Journal of Surgery 75:11, 952-952
CrossRef422
Christopher G Azzoli. (2005) Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?. Nature Clinical Practice Oncology 2:11, 552-553
CrossRef423
Coty Ho. (2005) Treatment of Late Stage Non-small Cell Lung Cancer: We Have More Work to Do. Southern Medical Journal 98:11, 1064
CrossRef424
(2005) Treatment of Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine 353:14, 1523-1524
Full Text425
Janessa J Laskin. (2005) Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care. Future Oncology 1:5, 619-623
CrossRef426
Eric M. Toloza, Thomas A. D’Amico. (2005) Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 17:3, 199-204
CrossRef427
J. D. Minna, M. J. Peyton, A. F. Gazdar. (2005) Gefitinib Versus Cetuximab in Lung Cancer: Round One. JNCI Journal of the National Cancer Institute 97:16, 1168-1169
CrossRef428
C. Manegold. (2005) Zukünftige klinische Entwicklung von Bevacizumab und Erlotinib. Der Onkologe 11:S01, 49-52
CrossRef429
Pisters, Katherine M.W., . (2005) Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer — The Smoke Clears. New England Journal of Medicine 352:25, 2640-2642
Full Text
- Letters
